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Drug discovery is the process through which potential new medicines 
are identified and brought into market. In 20th century, advances in technology 
have accelerated the processes of drug discovery. For instance, human genome 
project has identified more than 500+ proteins as druggable target. 
Combinatorial chemistry and solid phase chemistry have speed up the rate of 
compounds synthesis in 800 folds. It is an opportunity, but meanwhile a 
challenge. When look at above numbers, it is not easy to study the libraries and 
target proteins at such large scales especially considering the selectivity issues. 
To solve the problem, high-throughput screening (HTS) platform is required for 
lead compounds discovery. In this thesis, we have made use of microarray as a 
HTS platform for the specific ligand discovery of SH2 domains. Besides, our 
microarray has branched away from the exclusive pursuits of small molecule 
“hits” to proteomics, the large-scale studies of the performances of bioactive 
compounds in live cells.  
Once identified using HTS, hits need further optimizations to generate 
leads which have acceptable drug properties. However, in spite of the efforts, 
approximately 40% of currently marketed drugs and up to 75% of compounds 
currently under development have been suggested to be poorly water-soluble. 
The difficulty is more pronounced for macromolecules such as proteins and 
DNAs/siRNAs, which are regarded as emerging therapeutic agents. Therefore, 
we have established a highly efficient delivery system of drugs including both 
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Drug discovery is the process through which potential new medicines 
are identified and brought into market. The advent of genomic science, DNA 
sequencing, combinatorial chemistry, cell-based assays, and automated high-
throughput screening (HTS) has led to a new opportunity of drug discovery.1  
 
Figure 1.1. Overview of typical drug discovery process2 
 
For instance, human genome project has identified more than 500+ 
proteins as druggable targets.3 Combinatorial chemistry and solid phase 
chemistry have speeded up the rate of compounds synthesis in 800 folds. All 
these advances in technologies made it possible for rapid drug identification.  
It is an opportunity, meanwhile a challenge. When we look at above 
numbers, it is not easy to study the libraries and target proteins at such large 
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scales especially considering the selectivity issues. To solve this problem,  HTS 
technologies are required, which are capable of screening many protein 
interactions concurrently and sensitively at minimum cost. Over the last decade, 
microarray has been established as a robust HTS platform for rapid screening, 
lead discovery and molecular characterization.4-8 
Once the compounds (termed as “hits”) are identified via microarray 
screening, they would undergo evaluation in cell or animal models to validate 
their efficiencies in complex environment. Meanwhile, relevant drug properties 
such as toxicity, solubility, permeability, absorption, distribution, metabolism 
and excretion (ADME) are also tested. It is unlikely that the perfect compounds 
could be found within one-round screening. Always, further optimization 
related to SAR investigations is required.2  
In spite of the efforts on drug optimization, around 40% of currently 
marketed drugs and up to 75% of compounds currently under development have 
been suggested to be poorly water-soluble.9 It is not easy to deliver drugs to the 
target positions. The difficulty is more pronounced for macromolecules such as 
proteins and DNAs/siRNAs, which are considered as emerging therapeutic 
agents.10 Therefore, companies start to make use of macromolecular delivery 
systems such as cell-penetrating peptides (CPPs), liposomes and poly-cationic 
formulations to address these issues. 
After several rounds of optimizations, the surviving hits (now termed as 
“leads”) undergo preclinical and clinical trials. As shown in Figure 1.2, it is not 
until now that safety issues such as side-effects and “off-targets” are extensively 
investigated. Often, it is costly when drugs fail at these stages. To avoid the loss, 
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the development of platform for broad-based, proteome-wide screening at the 
outset of drug discovery is needed urgently. During this process, the target 
binding spectrums and key biological pathways affected by the leads are 
revealed at the early stage and thus miniaturized the loss. 
 
Figure 1.2. overview of pre-clinical and clinical phase 
 
In recent years, the development of activity-based protein profiling 
(ABPP),11 to some extent, alleviates the problem. By minimally modifying 
those drug-like compounds, the resulting probes enable the large-scale 
interrogation of protein small molecule interactions and the rapid identification 
of potential cellular targets in live cells.  
In this chapter, I would first introduce the protein and small molecule 
microarrays and their recent applications related to drug discovery. Secondly, I 
would give the detailed descriptions in the current strategies of protein delivery 
systems including CPPs, polymers and liposomes as well as their pros and cons. 
1.1 Microarray 
Over the last decade, microarray screening has transformed the life 
science research landscape. Novel applications such as molecular 
- 4 - 
 
 
fingerprinting, ligand discovery, protein expression profiling and interaction 
networks mapping, have significantly impacted both basic and applied 
spheres of research. Creative ideas by biologists, chemists and engineers are 
propelling this interdisciplinary technology to interesting new levels. The 
numerous successful examples have inspired a growing following of 
scientists to take on high-throughput, discovery-driven research, drawing 
impetus towards accelerated information assimilation and knowledge 
growth.  
Microarrays are miniaturised assemblies of molecule library 
organized across a planar surface.8 The size of library ranges from hundreds 
to tens of thousands. Each compounds of the library is identified based on 
the physical position on planner surface. Breaking away from tradition 
microtiter-based (or well-based) assays, the core feature of microarray is 
miniaturization and parallelization, allowing many different biological 
moieties available within a compact surface for massively parallel screening 
against multiple targets of choice to generate informative and comparable 
results while consuming low quantities of precious sample and analytes.  
Microarray technology is first introduced as miniaturized DNA 
assemblies on chips.12 After that, it does not take long before further 
pioneering efforts make it possible to immobilize small molecules, peptides 
and subsequently proteins in addressable grids for rapid analysis.13,14 Since 
then, we have witnessed the development in microarray technology and the 
emergency of innovative application based on various microarray-based 
platforms. 
- 5 - 
 
 
Traditional microarrays have been applied to the discovery of small 
molecule ligands or substrates for protein targets of interest. For example, 
peptide and small molecule serve as short substrates, inhibitors or ligands, 
which can be readily targeted by enzymes or other receptors. Large-scale 
screening on microarrays with those libraries against target proteins 
facilitates the discovery of specific binding motif, as well as the binding 
spectrums and preference of proteins and consequently accelerates the drug 
discovery process.  
In recent years, microarray has branched away from the exclusive 
pursuits of small molecule “hits”, to proteomics, the large-scale studies of 
the structures and functions of proteins.4,5,15 As reported, proteins regulate 
virtually every cellular process. The majority of diseases, including cancers, 
are characterized by the abnormal functions of certain proteins. The systems-
wide analysis of these abnormal functions leads to a comprehensive 
understanding of the intricate singling transduction pathways in diseased 
states, before and after treatment with drugs. This valued information 
facilitates the identification of target protein, validation of drug’s efficiency, 
understanding of drug mechanisms, and discovery of biomarkers that predict 
or guide therapeutic response. 
1.1.1 Discovery of Ligand, Inhibitor and Substrate 
Microarray-assisted “hit” discovery strategies can be classified into 
two categories: those are screened against recombinant proteins, and those 
are against cellular lysate.16  
For the first one, microarrays have been incubated with purified target 
proteins and the bindings are detected using readouts such as surface 
- 6 - 
 
 
plasmon resonance (SPR), fluorescently labelled antibodies against the 
proteins or the fluorescent tags on the proteins. This method has been used 
to identify probes of various types of proteins, including enzymes (such as 
kinase,17-19 proteases20-22 and decetylases23-25) as well as classically 
challenging proteins (such as growth factors and BRCT domains of BRCA1 
proteins).26  
In one recent example that highlighted the discovery of potent 
enzyme inhibitor, Lee and Park developed Jeffamine-coated slide which 
facilitated the reduction of nonspecific binding and thus enhanced the 
sensitivity. With such slides, 2, 4, 4’-trihydroxychalcone (Figure 1.3) was 
identified as a potent inhibitor of tyrosinase, a major regulator of melanin 
production (KD=0.4 µM).
27 The activity was confirmed by an inhibition 
assay that measured the catalytic rate of the tyrosinase-assisted conversion 
of L
-DOPA to DOPAchrome (IC50=0.76 µM). Further, it demonstrated that 
2, 4, 4’-trihydroxychalcone was able to treat melasma and 
hyperpigmentation, which were skin disorders resulted from abnormally 
high level of melanin.  
Apart from inhibitors which target the active sites of enzymes, 
microarray has also been applied to the study of protein-protein interactions 
(PPIs). PPIs control important regulatory pathways in virtually all cellular 
process. Inappropriate interactions between proteins are known to cause 
many human diseases. Compared to mainstream drugs, which usually bind 
to the active-sites, and have historically been the focus of pharmaceutical 
research, such inhibitors especially those made of small and cell-permeable 
molecules are attractive due to their generally better selectivity profiles. 
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However, the development of protein-protein interactions (PPIs) is perceived 
to be highly challenging. When referring to PPIs as targets in drug discovery, 
it appears to be that large protein-protein (PP)-contact surfaces (i.e. ~1500-
3000 Ǻ2) are involved, most of which are flat and often lacking in suitable 
pockets for small molecules to bind. 28,29 
In spite of the challenges, a number of successful examples have 
started to prove that it is possible to overcome these hurdles and develop PPI 
modulators as drugs.26,30-32 By integrating small molecule and peptide hybrid 
libraries and microarray technologies, our group has successfully discovered 
the cell-permeable inhibitor (15, Figure 1.3) against BRCT domain of 
BRCA1 protein with KD
 value from 250 nM to 1 µM range. In this setup, we 
first determined the preferred BRCA1 (BRCT)2-binding motif as 
RVFpSPVF using 1000-member combinatorial phosphor-peptide 
microarray. Then, the two flanking peptide fragments of pS residue were 
replaced by a library of commercial available acid and amine building 
blocks, representatively. A 51-membrane N-terminal library and a 50-
member C-terminal hybrid library were synthesized and anchored onto array 
to screen for potent binders of BRCT. After potent binders from each sub-
library were identified, the “hits” amine and acid building blocks were 
reconstituted to yield the final non-peptide small molecule inhibitors. 
Together with its non-hydrolysable analogues 15a and 15b, these small 
molecule like dipeptide compounds were shown to possess both in vitro and 
in cell antitumor activities via the disruption of BRCA1 (BRCT)2/protein 
interaction.  
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Compared to purified protein screening, recently, applying cell lysate 
to microarray has become more common. This format allows hits to bind 
targets with relevant post transcriptional modifications (PTMs) and interact 
with protein complex. This format also enables the discovery for proteins 
that cannot be purified. 
An impressive example of hits development for proteins using such a 
strategy related to nuclear protein pirin.33 Pirin is known to bind to Bcl3, 
whose overexpression level enhances the proliferation, survival and 
migration of many tumors. Osada and coworkers sought to identify small 
molecule probes of pirin in order to further characterize the cellular role of 
pirin. Using SMMs, the team screened >20,000 compounds from the RIKEN 
Natural Products Repository against pirin residing in cell lysate. Slides were 
incubated with HEK293T cell lysate with the overexpression of DsRed-fused 
pirin and the binder were detected via fluorescent readout. The positive hits, 
triphenyl compound A (TPh A, Figure 1.3) was used for further evaluation. 
Isothermal titration calorimetry (ITC) and crystal structure further illustrated 
the binding potency of TPh A to pirin (KD = 0.6 µM) and corresponding 
binding site (near Fe2+-binding site). Subsequent pull-down (PD) assay and 
cell-based experiments showed that TPh A was able to disrupt binding of 
pirin to Bcl3 and consequently inhibited cell migration. 
Recent, the applications of identified hit are not limited to compound 
lead. In certain instances, the hits were also transformed into probes, which 
enabled the broader identification and pull-down of the target proteins in 
cellular lysate.34-36 Also, they are converted to fluorescence polarization 
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(FP)-compatible binding probes for high-throughput assay, facilitating the 
discovery of small molecular inhibitors of PPIs.30  
 
Figure 1.3 Structure of ligand, inhibitor or substrate26,33,37 
 
1.1.2. Proteomic 
In the last decade alone, microarrays have evolved from being used 
primarily as basic analytical research tools into now viable options for more 
sophisticated applications in protein profiling, molecule interaction mapping 
and biomarker discovery. In this part, we elaborate on the studies of 
microarray applications which focus on two areas relevant to proteomics 
research: functional annotation and biomarker discovery. 
1.1.2.1. Functional Annotation 
With traditional protein screening assay, the functional annotation of 
target proteins is usually performed by incubating them with corresponding 
substrates in individual well. The activities of proteins are reported in forms 
of absorbance, fluorescence or luminescence signals. Similarly, microarray 
requires a platform where the enzyme activities can be converted to readable 
signals with minimal interferences from neighbouring proteins. In principle, 
protein microarray can achieve the goal, where thousands of proteins are 
immobilized and simultaneously characterized, and the activities can be 
identified in a high throughput way. However, since enzymes are catalysts, 
the corresponding substrates will not bond to the immobilized enzymes but 
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are easily washed away. That means the strategy used in microplate is not 
compatible with the fluorescence detection method used in slide-based 
microarray technologies. 
Activity based probes (ABPs), originally developed by Cravatt et al. 
in 1999 to study serine hydrolases, a mainly used to identify and 
characterized the activities of enzymes both in vitro and in vivo.38 As shown 
in Figure 1.4, such probes normally contain three key elements 1) warhead, 
which is able to direct the probe to the enzyme (class) and form a covalent 
bond with the target enzyme(s) based on the catalytic activity of enzyme(s); 
2) a reporter group, typically fluorophore tag for the visualization of labelled 
proteins; 3) a linker, which provides flexibility between reporter and 
warhead. Often, the activities of proteins are analysed by fluorescent gel or 
Western blot.  
 
Figure 1.4. Structure of ABPs and ABPP process39 
 
Inspired by ABPs, we developed the first microarray-based strategy 
for function annotation of enzyme activities in a rapid and reliable way. In 
this strategy, protein microarrays where active enzymes immobilized was 
treated with different ABPs, leading to selective covalent bindings between 
enzymes and the probes.40 The activities were identified based on the 
fluorescent signals from APBs (Figure 1.5). Once developed, our strategy 
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has been applied to different classes of enzymes including phosphatases, 
cysteine proteases and serine hydrolases.41,42 This enzyme assay was 
performed to reach two goals. First, this strategy allowed the high-
throughput identification and assignment of protein function by virtue of 
their enzymatic activities. Second, inhibition studies could be conducted 
using potential enzyme inhibitors, either general or specific ones, allowing 
simultaneously characterize and compare the efficiency of inhibitors towards 
different enzymes. Based on this strategy, Eppinger et al. and Funeriu et al. 
have developed a strategy to quantitatively determine kinetic constants on 
the chip according to the fluorescent readouts.43,44  
 
Figure 1.5. Principle of the activity-based detection of enzymes in a protein 
microarray with fluorescently-labelled, mechanism-based inhibitors.40 
 
Recently, a new surface concentration-based assay was development 
to determine the kinetic parameters of proteases on microarray.45 In this 
methods, a panel of rhodamine conjugated peptide substrates for MMP-3, 
calpain-1, caspase-3 and caspase-9 were immobilized onto maleimide-
functionalized slide. The activities of enzymes were quantified by 
calculating the surface concentration of substrate peptides cleaved on the 
array (dye-off measurement). According to the solid-phase standard curve, 
this new assay was able to generate kinetic data such as Michaelis constant 
(Km) and maximum velocity (Vmax). 
- 12 - 
 
 
By integrating ABPs with antibody microarray, Cravatt and co-
workers provided an alternative approach which enabled the proteomic 
profiling of enzyme activities on microarray platform.46 Proteomic was first 
incubated with fluorescence-tagged probes. Then, the labelled enzymes were 
then probed and identified by the antibodies on array.  
With those comprehensive understanding of the catalytic activity of 
enzymes, microarrays facilitated the definitions of new targets for the 
treatment of human diseases. By studying the phosphorylation patterns of 
paediatric brain tumors, Sikkema et al. have identified the elevated levels of 
Src family kinase activity in the tumors which could be targeted by the 
addition of kinase inhibitors, PP1 and dasatinib, leading to selectively 
induced death of these brain tumor cells.47 This strategy allowed a focused 
analysis into disease states, providing the opportunity to guide further 
therapeutic interventions. 
Microarray technologies also allowed the comprehensive 
understanding of intricate singling transduction pathways under disease 
states or with stimulations.  
For instant, antibody arrays could be used to detect the changes in 
protein expression levels and PMTs, which are induced by the presence or 
absence of bioactive compounds. Sokolov and Cadet have made used of 
protein microarrays to study the correlation between the expression levels of 
different proteins and the behavioural phenotypes of mice which were treated 
with methamphetamine (METH).48 As reported, METH abuse has been 
shown to stimulate aggressive behaviours in humans and in other animals. 
The author found that the repeat treatment of METH on mice induced the 
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deregulation of mitogen-activated protein (MAP) kinase pathway and finally 
increased aggressiveness and hyper-locomotion. In this work, 378 antibodies 
specific for proteins related to signal transduction, cell cycle regulation, cell 
structure, apoptosis, oncogene products and neurobiology were used to 
prepared microarray. The antibody microarray was incubated with 
fluorescent labelled protein extractions from METH treated mice. The results 
indicated that the level of Erk2 and 14-3-3e decreased in the striata of the 
mice treated with METH. Since Erk2 was regarded as a principle component 
of the MAP kinase pathway when protein 14-3-3e was an inhibitor of kinase 
C, the reduction in these two proteins suggested that repeated exposure to 
METH might alter MAP kinase-related pathway involved in behavioural 
changes. 
In another example, Lackner and co-workers have developed a 
reverse-phase protein array (RPPA) to test the phosphorylation status of 100 
proteins in different breast cancer cell lines.49 Cell lysates from different cell 
lines were immobilized onto slide in serial dilutions and detected by various 
phosphorylated-recognized antibodies. This study allowed the group to carry 
out signalling pathway analysis in HTP way and classify breast cancer cell 
lines into different subtypes according to the slight differences in fingerprint. 
Furthermore, such analysis provided valuable information on the deregulated 
signalling pathways in individual cancers. 
1.1.2.2. Biomarker Discovery  
Furthermore, the availability of systematic and general HTP 
platforms to measure the changes across cellular states is helpful to 
understand the characteristics of unique diseases at the proteomic level.  
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Readdy et al. compared serum samples from both healthy persons and 
patients with Alzheimer’s disease (AD) using peptide microarrays.50 The 
samples were incubated on microarrays comprised 15,000 structurally novel 
peptides, and IgG binding patterns before visualized using secondary 
antibody. Three AD peptides were identified from the screening, and further 
characterization revealed at least two candidate auto-antibody biomarkers 
for AD.  
Microarrays, as mentioned above, are HTS platforms which meet the 
requirement of large scale studies. In this part, we mainly talk about small 
molecule and protein microarrays. At early stage, the applications of 
microarrays mainly focus on the discovery of inhibitors, substrates and 
ligands. In recent years, microarray technologies are not limited to 
recombinant proteins but be used in more complex systems, helping 
researcher to have comprehensive understanding about the native cellular 
environment. 
1.2 Cellular Delivery 
Often, the drug candidates from microarray screening suffer from 
hydrophobicity and low water solubility issues. First of all, combinatorial 
synthesis and HTS are carried out in non-aqueous media (DMSO etc.) which 
decreases the possibilities of aqueous hits discovery. Second, the demands of 
increase potency, coupled with the theory that the binding potency is mediated 
by hydrophobic interactions, further magnifies the likehood of hydrophobic 
drug candidates. Third, current drug targets, such as lipids, process proteins or 
highly lipophilic ligands, which prefer to interacting with highly lipophilic, 
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poorly water-soluble drug candidates, amplifies the requirement. Therefore, in 
spite of efforts made during lead optimization, approximately 40% of currently 
marketed drugs and up to 75% of compounds currently under development have 
been suggested to be poorly water-soluble.51,52 Due to the hydrophobicity, such 
drug candidates tend to be low or variable bioavailable, causing variability in 
clinical responses. Hence, it is urgent to develop methods for efficient delivery 
of such drugs into cells. 
Beside small molecule drugs (SMDs), the other class is “large molecule” 
biologics including sugars, nuclei acids, recombinant therapeutic proteins or 
complex combination of these substances. Among these, therapeutic proteins 
are attractive and have been used to treat a variety of medical conditions where 
SMDs are not available. Compared to SMDs, proteins often generate highly 
binding affinity and specificity that cannot be mimicked by simple chemical 
compounds. Also, due to their highly specificities, there is less potential for 
protein therapeutics to interfere with off-target proteins or cause side-effect. 
Therefore, protein therapeutics have a significant role in the field of medicine. 
However, the applications of such strategies are limited by the low cellular 
delivery efficiency due to the high molecular weight, the polarity of therapeutic 
proteins and their poor stability against proteolytic and hydrolytic degradation. 
Since the first discovery of TAT peptide, a variety of methods have been 
developed in the last 20 years, including the use of cell-penetrating peptides 
(CPPs),53 super-charged proteins,54 liposomes,55 nanoparticles (NPs)56 and 
polymers.57 Based on their principle, these methods can be classified into three 
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catalogues, mechanical delivery methods, covalent protein modification and 
supramolecular delivery systems.58  
1.2.3. Mechanical Delivery Methods 
Mechanical delivery methods such as microinjection and 
electroporation are the most traditional strategy. These strategies enable the 
delivered protein to be direct access to the cytosol which are very useful for in 
vitro investigation. However, such strategies are low-throughput, invasive and 
require specialized equipment. All these dramatically limited the applications 
of mechanical delivery. Further, the transit cell permeabilization might 
introduce undesired biomolecules into cells and thus cause side effect.  
1.2.4 Covalent Protein Modification 
1.2.4.1 Cell-Penetrating Peptides (CPPs) 
 CPPs are generally peptides of less than 30 amino acids derived from 
natural or unnatural proteins or chimeric sequences that have the capability to 
cross cellular membranes via energy-dependent and/or independent 
machanisms.53,59  
It is first found by Frankel and Pabo, who show that the transcription 
trans-activating protein (Tat) of HIV-1 could enter cells and translocated into 
nuclear.60 In 1991, the group of Prochiantz demonstrated the similar property of 
Drosophila Antennapedia homeodomain.61 Three year later, the first CPPs, a 
16-mer-peptide driven from the third helix of the homeodomain termed 
penetratin, was discovered. After that, a batch of CPPs has been developed. 
However, it was until 1999 that Dowdy proved that CPPs enabled the delivery 
of small peptide and large proteins.62 Until now, CPPs have been applied for the 
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delivery of synthetic and biological components into cells including enzymes, 
cytokines, apoptotic molecules, protein hormones, molecular chaperones and 
cell-signalling proteins.58  
Generally speaking, most CPPs are positively charged peptides 
containing a few of basic residues and hydrophobic residues. Among these 
amino acids, basic residues facilitate CPPs to bind to the negatively charged 
proteoglycans and phospholipids on the cell surface via electrostatic interaction. 
Hydrophobic residues play a major role in the interaction with the plasma 
membrane bilayer via hydrophobic interaction. It has been demonstrated that 
both basic and hydrophobic interactions strongly affect the translocation 
efficiency and mechanism.63,64  
In spite of these knowledges, the mechanism of cell uptake of CPP-
tagged materials remains a matter of debate.65 Original hypothesis suggested 
that CPPs worked by penetrating the cell membrane through translocation 
which enabled the direct access to cytosol. But further experiment indicated that 
the uptake occurred through endocytic mechanism. Currently, the more 
acceptable theory is that both endocytosis and direct translocation across the 
plasma membrane are involved in the uptake process. Besides, recent study 
suggests that a receptor-mediated entry is not ruled out for some CPP-
conjugates. Generally speaking, several parameters including molecular weight, 
the nature of linkage, the cell line and the concentration affect uptake 
mechanism.66-68 Nevertheless, endosomal entrapment and subsequently 
lysosomal degradation are the most challenging issues for CPPs assisted 
strategies. It is reported that CPPs linked proteins tend to rapidly concentrate 
- 18 - 
 
 
inside the endocytic organelles. As a result, the delivery efficiencies are 
dramatically decreased since only little protein is able to escape from endosome, 
reach its extra-endosomal target and exert its biological activity. Furthermore, 
macromolecules are subjected to degradation by acidic pH or hydrolases when 
they are trapped in late endosomes or lysosomes.69 
To address this issue, several strategies have been developed to improve 
endosome escaping efficiency, including pH- and temperature-induced 
modulators, synthetic endosomal lysis agents (cyclic CPPs and multivalent 
CPPs), and photo-induced physical disruption.58,69,70 However, the efficiencies 
of cytosolic access of these strategies are in doubt. 
1.2.5. Supramolecular Delivery System 
1.2.5.1. Liposome 
Liposomes is one the nano-carrier (typically 50-500 nm in diameter), 
consisting of a lipid bialayer.71 The formation of liposomes is a spontaneous 
process enabled by the interactions between water molecules and amphiphilic 
lipid molecules. Once completing, an aqueous volume becomes trapped within 
the core of liposome, giving liposome the ability to selectively sequester solvent 
for encapsulation, and thus form the basis for drug delivery. 
Compared to the rest of delivery systems, the most interesting feature of 
liposome is the mechanism. As the bilayer of liposome closely mimic those of 
cells, they can be directly fused to the membrane. Even if the liposome is 
uptaken through the endocytosis, the bilayers enable the cargos to escape from 
endosome either by disrupting endosome membrane or by fusing with the 
membrane. 
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It is able to fabricate different types of liposome drug delivery vehicles 
based on the composition of the bilayers. By incorporating antibodies, ligands, 
polymers and peptides into the bilayers, liposome delivery can achieve pH-, 
temperature and photo-induced controllable release as well as target delivery.72-
76 
In recent study, Ping and co-workers have devised a novel type of 
multistage pH-responsive liposomes (HHG2C18-L) for tumor target drug 
delivery (Figure 1.6).77 The key component was 1, 5-dioctadecyl-L-glutamyl 2-
histidyl-hexahydrobenzoic acid (HHG2C18), a zwitterionic oligopeptide lipid. 
This lipid could mixed with soy phosphatidylcholine (SPC) and cholesterol to 
generate the smart liposomes, whose surface charge changed based on the 
environment pH value. Under physiological pH value (7.2-8.0), such liposome 
had strong negative charge surface charge (-22.8 mV) but changed sharply to 
+6.3 mV due to hydroxybenzoic acid (HBA) near tumor microenvironment. 
Consequently, the charge conversion facilitated the tumor cellular uptake. After 
that, a second-stage pH response occurred when the liposome entered 
endosomes and/or lysosomes where pH value decreased to 5.5. As a results 1) 
The imidazole group of HHG2C18 facilitated proton influx to endolysosomes, 
resulting in endolysosomal escaping and 2) HBA was cleaved in the acidic 
environment to generate HHG2C18-L which facilitated the mitochondria-target 
delivery of anticancer drugs. 




Figure 1.6 Schematic design of the smart liposomes (HHG2C18-L) with 
multistage pH response to the tumor extracellular matrix and intracellular 
compartments for mitochondrial-targeted anticancer drug delivery.77 
 
Since the first example demonstrated the liposome-mediated carrier as a 
useful tool for functional protein delivery,78 it has proved that liposome-based 
methods enable the delivery of various target proteins into both adherent and 
suspension cells while retain the activities of those cargos. However, their 
delivery efficiencies vary significantly depending on protein size/charge since 
liposome-based methods make use of electrostatic/hydrophobic interactions for 
complex formation with target proteins.79 
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Further, such strategies are limited by its low loading amount (generally 
< 30% for active loading) due to the limited entrapment volume, the protein 
solubility and the poor stability.80 A report indicates that a freeze-thaw cycling 
process would enhance the loading amount, but such a process is risky with the 
regard to loss of protein activities. 
1.2.5.2. Polymer 
Cationic polymers including polyethylenimine (PEI), poly(L-lysine) 
(PLL) have been widely used for drug delivery via endocytosis.81 Once 
delivered, the carriers enable cargos to escape from endolysosome through 
“proton sponge effect”, during which multivalent amine-containing polymer  
absorb protons, build up osmotic pressure in acidic organelles and finally cause 
the broken of endosome or lysosome. However, in spite of its wide applications, 
cationic polymers are somehow cytotoxic due to its large molecular weight and 
high surface cationic charge density.  
To alleviate the problem, block copolymers containing a cationic block 
and a PEG block are introduced. In the copolymers, cationic blocks are 
responsive for cellular delivery while the PEG blocks form an exterior hydration 
layer that shields the cationic charge as well as stabilizes the complex. Further, 
moieties that facilitate the uptake or targeting capability can also be modified 
on PEG, making such a design an effective way for protein delivery. For instant, 
PLL-co-PEG block polymer was synthesized with folic acid (FA) linked to the 
end of PEG chaine.82 In the system, PLL was responsible for the cellular uptake 
while folic acid was a targeting agent that recognized the folic acid receptor 
overexpressed by a variety of cancer cells. As a result, the cellular uptake was 
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largely enhanced in folate receptor overexpressed mouth epidermal carcinoma 
cells. 
Beside, a variety of other biodegradable polymer backbones (polymer 
polyamidoamine (PAMAM), poly(amino-co-ester)s (PAE)) and structures 
(linear, branched, and dendritic architectures) have been also tested.83,84  
In recent years, the development of stimuli-sensitive systems for protein 
delivery has been a subject of significant pharmaceutical importance, as the 
systems can recognize environmental changes, induce structural changes, and 
release therapeutic proteins in a responsive manner. With different building-up 
monomers, various stimuli-responsive polymer-assisted delivery strategies 
including temperature, pH, photo, redox potential bio-responsive systems have 
been built up.85-87  
A particular interesting example of dendrimer-based delivery is shown 
by Yao and colleagues, who used carboxymethyl (CM) chitosan-
poly(amidoamine) (PAMAM) dendrimer core-shell nanoparticles to load and 
release lysozyme.88 In this system, PAMAM formed a hydrophobic negatively 
charged core which facilitated the loading of positively charged lysosome at 
physiological pH value. Outside, the negatively charged CM chitosan served as 
shell at pH 7.4. When pH decreased to 5.1, the protonation of amino groups in 
CM-chitosans and tertiary amines in PAMAM led to a strong electrostatic 
repulsion in CM-chitosan-PAMAM, triggering the release of encapsulated 
drugs. Compared to previous generated CM-chitosan polyion micelles, these 
new dendrimer nanoparticles have better loading capacity, higher pH sensitivity 
and less cytotoxicity. 




Figure 1.7. Overall strategy of CM chitosan-PAMAM delivery system. (A) 
Schematic representation of the encapsulation and release mechanism of 
lysozyme from CM-chitosan/lysozyme PIC nanoparticles. (B) Schematic 
representation of synthesis and self-assembling for CM-chitosan-PAMAM 
dendrimer nanoparticles, and the encapsulation and release mechanism of 
lysozyme from CM-chitosan PAMAM/lysozyme PIC nanoparticles.88 
 
Further, with sophisticate design, blocks with different functions can be 
combined together to generate multi-controllable co-polymer system.89 Redox 
sensitivity of polymers may be combined with pH-responsivity by 
copolymerization of polyethylenimine (PEI) with polylactic acid (PLA) via 
redox sensitive disulfide bonds to generate dual responsive polymer system. 
Under physiological pH value (7.4), such polymers had negative charge surface 
charge at around -10 mV but changed sharply to +15 mV when pH came to 6.8. 
Consequently, the charge conversion together with the folate ligand (FA) 
facilitated the tumor cell uptake. When polymers entered endosomes and/or 
lysosomes, their surface charge further increased to +20 mV, facilitating 
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endosome escaping of polymers through “proton sponge effect”. Once into 
cytosol, disulfide bonds would be cleaved by GSH of high concentration, 
resulting in the high efficient release of anticancer drugs. 
 
Figure 1.8. Schematic design of the targeted micelles (PELE/DA-FA) with 
charge reversal to the tumor extracellular matrix and intracellular GSH-
triggered drug release.89  
 
1.3 Objective 
The objective of this thesis is to use SMMs as HTS strategy for the 
identifications of the specific ligands which are able to disrupt PPIs (Chapter 2). 
Further, microarrays are applied to proteomic profiling. By uniting protein 
microarrays with in situ profiling, we have established a platform for high 
throughput identifications of on- and off- targets of those drug candidates in live 
cells (Chapter 3). In addition, the highly efficient delivery system of drugs 
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including both small and large molecule is established with cell penetrate 
poly(disulphide)s (Chapter 4). 




Profiling human Src homology 2 (SH2) domain 
proteins and ligand discovery using a peptide-
hybrid small molecule microarray 
Summary 
 
In this chapter, a 396-member peptide-hybrid small molecule 
microarray was fabricated to profile small molecule ligands across 15 SH2 
proteins, yielding hits against Lck and Grb2.  
2.1 Introduction 
Src homology 2 (SH2) domains are readers of tyrosine kinase 
phosphorylation. By binding phosphorylated target sequences, these domains 
relay signals downstream to effect cellular regulation and gene expression 
control.90-92As a result, they form critical components of cell signalling 
networks. Over 110 human proteins contain SH2 domains, including kinases, 
phosphatases, transcription factors and adaptor proteins.90,91These proteins are 
over-expressed in various diseases, including cancer, and hence represent key 
targets for modulation using therapeutics.90-92 Through in vitro and in silico 
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screens, various peptide and small molecule inhibitors have been identified 
against SH2 domains.93,94 Herein, we present a small molecule microarray 
(SMM) strategy for rapid fingerprinting and profiling of SH2 proteins, which 
enables rapid molecular characterization and comparative inhibitor profiling.   
Various methods have been applied to map the interaction preference of 
SH2 domains,95-97 particularly more recently through the use of microarrays.98-
101 For example, Huang et al. have mapped the binding motifs for 76 SH2 
domains against phosphopeptides using SPOT synthesis/macroarrays.99 Using 
this map, SH2 domains have been classified into three groups (I, II, III). While 
the binding specificity of SH2 domains is attributed largely to the C-terminal 
segment of the phosphorylated targets, residues at the N-terminus also 
contribute to overall binding potency.95-97,99 
In order to further examine the binding preferences of various SH2 
domains and facilitate inhibitor discovery, we have built a novel 
phosphopeptide-hybrid small molecule microarray to investigate this class 
proteins. We designed and fabricated a 396-member library of small molecules 
containing a centrally located phosphotyrosine flanked by 9 N-terminal 
dipeptides and 44 C-terminal small molecule building blocks (Figure 2.1). The 
objectives of this strategy were to 1) significantly expand the specific binding 
preference of SH2 C-terminal pockets from traditional peptide-centric 
approaches to small molecule-centric strategies, 2) profile the binding spectra 
across multiple SH2 domains and identify selective small molecule building 
blocks which can bind the C-terminal pocket, and 3) identify complementary 
N-terminal sequences that could enhance binding efficacy and selectivity. 




Figure 2.1. Overall strategy of the screening SH2 domain containing proteins 
against a ligand microarray for high-throughput profiling.102  
 
2.2 Library Synthesis  
The general strategy is shown in Figure. 2.1. A panel of SH2 domain 
proteins were individually expressed and purified using a one-step labelling and 
purification approach. The library was synthesized using 9 different N-terminal 
sequences from known SH2 binding targets and 44 commercially available 
amine building blocks whose structures cover aromatic, aliphatic, cyclic and 
bicyclic compounds (X1-44; Figure. 2.2). A Biotin-Gly-Gly linker was added to 
facilitate compound immobilization onto avidin- functionalized glass surfaces. 
Synthesis was carried out on solid phase using PL-FMP resin and Irori 
MicrokanTM reactors (Scheme 2.1). Following acidic cleavage and ether 
precipitation, representative compounds were dissolved in DMF and run on LC-
MS, to ensure purity was > 80%, and the MS of the final product was correct. 




Figure 2.2. Design and synthesis of the 396-member SH2 ligand library.102 
(A) C-terminal substituents comprising of 44 different amine building 
blocks. Highlighted in red are the C-terminal structures from the 14 hits 
identified using the SMM screening results. (B) Original peptide sequence 
motifs for the selected 9 SH2 N-terminal substituents (in blue). 
 
 
Scheme 2.1. SH2 library synthesis.102 (a)(i) amine building block/EDC, 2 h; 
(ii) 1% HOAc/Na(OAc)3BH, 16 h; (b) (i) Fmoc-Tyr[PO(OBzl)OH]-
OH/PyBrOP/DIEA, 12 h; (c) (i) 20% piperidine/DMF 1 h; (ii) Fmoc-AA-
OH/HOBt/HBTU/DIEA/DMF, 12 h; (d) TFA/TIS/H2O (95 : 2.5 : 2.5). 
 
2.3 Microarray Fabrication and Screening  
Microarrays were spotted with the 396-member library in duplicate. To 
confirm immobilization, slides were stained with a phosphor specific binding 
dye, ProQ Diamond®. All spots displayed a positive signal, confirming 
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immobilization of the library across the slides (Figure. 2.3). The intensities of 
the spots were not uniform. This phenomenon was observed in previous 
experiment. It might be because of the residues next to phosphor-typrosine that 
affected the binding affinity of ProQ. Proteins were expressed in E.coli with 
hexa-histidine tags, and were labelled on beads with Cy5-NHS (GE Healthcare), 
before being eluted with imidazole and size separated (using a G-25 Nap 
column, GE Healthcare), facilitating labelling and purification in a combined 
step. A total of 15 fluorescent labelled SH2 proteins were prepared in this 
manner (Figure 2.4), and screened against this small molecule library on 
microarrays. A 10 µM concentration of protein was applied to each slide. 
Following a wash cycle with PBS containing 0.1% Tween, the fluorescent 
scanned images were obtained (Figure 2.5). The microarray data was extracted, 
background subtracted, normalized, and displayed in a coloured heatmap 
(Figure 2.6). The labelling efficiency varied among different SH2 domains. We 
further confirmed that when the arrays were dephosphorylated through alkaline 
phosphatase treatment, no binding was observed. This highlighted that binding 
to the SMM was dependent on SH2 domain interactions, as well as on the 
presence of a phosphorylated Tyr residue (data not shown).  
 
(A) 




Figure 2.3. Microarray fabrication.102 (A) Print code of the 396 library (B) 
ProQ image of 396 member library. 
 
 










Figure 2.5. Microarray image of 15 SH2 proteins102 
 
2.4 Ligand Fingerprint  
The complete dataset is shown in Figure. 2.6 as a coloured heat map. 
Each of the 15 SH2 domains exhibited characteristic fingerprints. Based on 
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these results, several broad conclusions could be drawn. Generally it appeared 
that positions with N-terminal PP, VV or PI sequences generated unique hits, 
more so than any other N-terminal sequence. Also, the heat map showed that 
the class II SH2 domain containing proteins exhibited a binding pattern that was 
rather distinctive.  
  
 
Figure 2.6. Coloured heat maps displaying intensities with each of the ligand 
(scale inset).102 Src (a), Lck (b), Abl1 (c), Abl2 (d), Sh2d1a (e), Ship2 (f), 
Crk (g), Brk (h), Bcar3 (j), Bmx (i), Grb2 (k), Sh3bp2 (l), Shc1 (m), Shb (n), 
Socs2 (o). 
 
As the dataset was extensive, we further simplified the results for 
analysis by first averaging the complete microarray dataset formed by 
contributions of signals from the respective N-terminal and C-terminal 













a b c d e f g h i j k l  m n o 
Class      I II
100%0%
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SH2 domains into their classes (12 proteins in class I and 3 proteins in class II, 
Figure 2.1), it was revealed that a common set of C-terminal substituents for 
class I proteins, namely 12, 25, 36 and 37, which were long chain ring 
containing compounds, while 1, 5, 6 and 10 which contained cyclic rings linked 
proximately to amine displayed good affinity across the proteins tested. 
Compared to those of class I, class II proteins displayed a distinct preference for 
binding to aromatic groups with short chains such as 16, 17, 22, and 31. This is 
consistent with a previous study claiming that class II SH2 domains prefer a 
hydrophobic residue at the P1 position.99 
                             N-terminal                                                            C-terminal                                  
    
 












Figure 2.7. Average binding contributions across N-terminal peptide 
sequences (Left) and 44 C-terminal small molecule building blocks (Right). 
Each bar represents averaged binding across in the library presenting the 
relevant peptide sequences. The error bar denotes the standard deviation 
across each group.102  
 
In addition, these averaged results also showed that the N-terminal 
positions also contributed significantly to the binding, as evidenced by the 
sizeable error bars (Figure 2.7). Across class I SH2 proteins, PP, PI or VV 
sequences had a clearly higher contribution to overall binding, compared to the 
other 6 N-terminal sequences tested. For class II SH2 domains, there was a 
broader preference with proline containing P1 members contributing towards 
the strongest relative binding. This result was consistent with references 
describing favourable contribution of hydrophobic residues on the N-terminus 
to overall inhibitor potencies.99,103To further resolve the groups according to 
binding preference, hierarchical clustering was carried out. This, unlike 
sequence homology clustering usually performed,90 categorizes SH2 domains 
according to their binding preferences against ligand libraries.104  




Figure 2.8. Cladograms of SH2 domains based on binding fingerprints102 
 
Our clusters generally grouped class I and class II proteins separately 
(Figure 2.8). Class I SH2 domains all contained a Tyr or a Phe aromatic residue 
at βD5, which has been shown to influence binding at P1 and P3 positions.96 
These included namely Src, Abl1 and Lck. Lck, Src, Abl1 and Abl2 from group 
I share a common pY-E(L/E)I binding preference,4b which can account for the 
similarity observed. Shb, Socs2 and Shc1were grouped most distantly from the 
majority of other group 1 SH2s, as might have been expected. In particular, 
Socs2 and Ship2 formed a sister pair indicating a highly similar binding profile, 
as did Grb2 and Sh2d1a, highlighting the clustering based on the microarray 
fingerprints correlated closely with traditional substrate grouping across these 
SH2 domains.99  
2.5 Ligand Identification and Validation 
In addition to fingerprinting, we also identified several strongly binding 
molecules that appeared to be potential hits. They showed significant levels of 
fluorescence on the microarray screens, across various SH2 proteins. A total of 
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14 such hits were identified for follow-up validations and tests (Table 2.1). 
These hits were resynthesized, purified and LC-MS analysis was conducted, to 
confirm purity and identity. These molecules were re-spotted on smaller sub-
grids of avidin slides, and subjected to concentration-dependent applications of 
various SH2 proteins. As a result, apparent KD values were computed for these 
hits against the various SH2 domains, as shown against Lck (Figure 2.9). Based 
on these results, PP-pY-X5 and PP-pY-X25 were identified as hits that bound to 
both Lck and Grb2, and PI-pY-X1 appeared to be a potentially selective hit for 
Grb2.  
 
Table 2.1. Structures of 14 potential binders identified102 




Figure 2.9. Concentration dependent application and apparent KD results for 
selected hits.102 (A) Grid arrangement. (B) Pro-Q image of the potential 
binding hits indicating successful immobilization (top grid in green). 
Concentration-dependent screening of the microarray against Cy5-labeled 
Lck(bottom grids in red). (C) KD analysis of selected compounds. (D) 
Summary of KD values obtained from the microarray experiment. TMR - 
tetramethylrhodamine (spotted dye reference). 
 
Further validation was carried out by a protein thermal shift assay using 
thermal shift measurements for both Lck and Grb2, using methods previously 
described.105 Lck without a ligand acted as a negative control, with the melt 
temperature of about 55.4 1 oC. After adding the ligand, the melting point shift 
increased due to the stability of the protein–ligand complex. Compared to the 
melting point of the negative control, all ligand–protein complexes presented a 
right shift ranging from 55.7 to 58.6 1 oC. The shift range was proportional to 
the binding potency of the hits. For instance, PI-pY-X1 produced a small 
thermal shift (0.3 oC) while the stronger Lck binding hits PP-pY-X5, PP-pY-X6 
and PP-pY-X25 contributed to larger shifts (~3 
oC). The results indicated that 
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the latter three hits were true binders. Similarly, the thermal shift results of Grb2 
matched that expected from the microarray results. Among the hits tested, PP-
pY-X5 and PP-pY-X25 and PI-pY-X1 presented as hits for Grb2. Taken together, 
PP-pY-X5 and PP-pY-X25 broadly bound Grb2 and Lck, while PI-pY-X1 bound 
Grb2, but only weakly bound Lck (Figure 2.10). Future docking or co-
crystallization experiments could confirm the binding pockets and orientation 
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Figure 2.10. Results of thermal shift assay.102 (A) Representative unfolding 
curves of Lck-SH2 domain obtained from protein thermal shift assay. (B) 
Representative unfolding curves of Grb2-SH2 domain obtained from protein 
thermal shift assay. (C) Result of protein thermal shift assay 
 
2.6 Conclusion 
In conclusion, we have successfully fabricated a small molecule 
microarray platform which enables, for the first time, convenient profiling of 
SH2 domains with small molecule building blocks. In the present format, the 
binding profiles were sufficiently distinct to produce informative fingerprints 
that clustered the various SH2 domains according to their expected functional 
classes. In addition, we have identified putative small molecule hits against 
Grb2 and Lck. These peptide-hybrid compounds, though not explicitly 
demonstrated herein, might in future be converted into cell permeable small 
molecule protein-protein interaction (PPI) inhibitors.106 It will be possible to 
monitor slight differences in binding using a multi-coloured labelling and 
application strategy.107,108 Overall this SMM strategy offers an attractive 
approach for performing global selectivity screens of SH2 domains against a 
much larger set of diversity elements. 
  




Accelerated cellular on- and off-target 




In this chapter, in situ proteome labeling was carried out with 9 drug-
like probes in live mammalian cells, with the corresponding cellular targets 
captured on microarrays and simultaneously screened using a diverse set of 
antibodies, revealing potential on- and off-targets. 
3.1 Introduction  
Drug discovery is a long-drawn and expensive process, partly due to the 
unexpected behaviour and off-target binding spectrum of drug candidates.109 
Often, side-effects become evident only at the late stages beyond lead 
development, particularly during pre-clinical and clinical trials, by when 
failures are costly. The ability to perform broad-based, proteome-wide 
screening at the outset of drug discovery introduces a new paradigm, where the 
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target binding spectrum and key biological pathways affected are revealed and, 
if necessary, tuned upfront. Such a drug development approach will enhance 
candidate success, and also provide an informative toolbox for pre-empting 
multi-drug reactions and even facilitating combination drug therapy.110,111 In the 
last several years, by borrowing from concepts in the field of activity-based 
protein profiling (ABPP),11 in situ drug profiling has become possible using 
drug-like chemicals minimally modified from their parental compounds. Such 
drug-like probes enable the large-scale interrogation of protein−small molecule 
interactions and can rapidly identify potential cellular targets, both on- and off- 
targets, in live cells.112-114 One of the main challenges, however, is with the 
target validation step (Figure 3.1A; workflow on the right); upon protein 
labelling, pull-down (PD) experiments are usually required, followed by 
Western blot (WB) analysis, to confirm the genuine in situ target-probe 
interactions. The process is cumbersome, expensive and low-throughput.115-117 
Microarrays are ideal for selectivity screening, because of their low cost, 
vast scalability and throughput.5,46  However, there exist no approaches for 
microarrays to contribute to functional drug selectivity screening in situ. Herein 
we report a variant of reverse phase protein microarrays,118 to unite the in situ 
drug profiling and microarray approaches for the first time, in order to rapidly 
identify and/or validate on- and off-targets of bioactive compounds (Figure 
3.1A; left).        
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3.2 Microarray Fabrication 
The proposed microarray target screening approach is depicted in Figure 
3.1A. Nine bioactive compounds were first minimally tagged with an alkyne 
handle, with or without an alkyl diazirine photo-crosslinker to generate the 
corresponding affinity-based probes (AfBPs) or activity-based probes (ABPs), 
respectively (Scheme 3.1).117,119,120 The AfBPs/ABPs were incubated with 
recombinant proteins, spiked cell lysates or living cells, to initiate protein 
labelling. Thereafter, the labelled reaction was clicked with an azide-containing 
trifunctional linker (Figure 3.1B), using copper-catalyzed alkyne-azide 
cycloaddition (CuAAC).121,122 As the trifunctional linker also contained 
rhodamine and biotin units (for imaging and protein capture, respectively), the 
resulting samples could be directly spotted onto avidin-coated slides, where 
labelled proteins were captured across multiple sub-grids. The arrays were then 
probed with antibodies (Abs), representing putative targets. To ensure high-
sensitivity detection, tyramide signal amplification (TSA) was employed.11 
Potential advantages of this strategy include 1) scalability and throughput in 
probing drug-target interactions in vivo, 2) simultaneous and quantitative 
comparisons across various dimensions (protein targets, compounds and cell 
types), and 3) ease of use with minimal quantities of reagents and antibodies 
required. Similar experiments, if conducted by classical PD experiments, 
followed by in-gel fluorescence scanning and WB analysis (Figure 3.1A; right), 
remain cumbersome, and require large quantities of expensive antibodies.  




Figure 3.1. (A) Overall strategy of the microarray-guided, target 
profiling/validation of drug-like compounds. (Left) Following click 
reactions and immobilizations on to microarrays, the samples were probed 
with multiple antibodies (Abs) and detected with tyramide signal 
amplification (TSA). (Right) Traditional PD/WB workflow for target 
validation. (B) Structure of the tri-functional linker containing rhodamine, 
azide and biotin units.  
 
The 9 probes used in this study were derivatives of bioactive compounds 
targeting protein kinases (STS-2, DA-3, PU-1, PD-1, IM-1 and CC-1),117 
protein disulfide isomerases (PDI) (P1 and 16F16A) and bromodomains 
(IBET-1) (Scheme 3.1).119,120 These classes of proteins are vital targets for a 
host of human diseases, ranging from cancer to neurodegenerative disorders. 
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The compounds were modified minimally from the original inhibitor using an 
aliphatic alkyne linker, which in the case of reversible inhibitors also included 
a diazirine moiety to facilitate covalent, UV dependent, target capture. The 
linker was inserted at the solvent accessible site, which preserved target binding 
properties of the compounds.117,119,120 
 
Scheme 3.1. Structures of 9 minimally modified drug-like compounds for 
target profiling. All probes were previously reported.117,119,120 
 
3.3 Pure Protein and Spiked Lysate Profiling 
To prove the concept, we first selected a protein tyrosine kinase, c-Src 
and its corresponding antibody, together with 3 AfBPs (STS-2, DA-3 and 
IBET-1). c-Src was expected to bind both STS-2 and DA-3 while IBET-1 was 
expected to exhibit low or neglibible affinity with this biological target. c-Src, 
at a concentration of 1 mg/ml, was incubated with the probes. Following UV 
initiation and the click reaction,115-117 excess unreacted probes were removed by 
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acetone precipitation. The labelled samples were serially diluted and spotted 
onto avidin-coated glass slides in a concentration dependent manner (1, 10, 100, 
1,000, 10,000 ng/ml).104 Following a 2 h incubation, the slides were extensively 
washed with TBST (0.5% Tween20), probed with anti-c-Src antibody, and 
visualized with TSA-Cy5 detection system.35 The set of experiments were 
conveniently replicated across multiple subgrids on the same slide, with good 
reproducibility (Figure 3.2A). The array results were also plotted graphically 
(right); c-Src was shown to be captured most effectively by STS-2, followed by 
DA-3, with readable signals even at the lowest 1 ng/ml concentration. At the 
highest concentration of c-Src used (i.e. 10,000 ng/ml), only slight signals were 
detectable with the IBET-1 probe. Nevertheless, there was a clear 
concentration-dependent trend. (Figure. 3.2) These binding profiles with each 
of the 3 probes were consistent with in-gel fluorescence scanning results (Figure 
3.2), which was obtained by detecting the rhodamine from the trifunctional 
linker. While this initial experiment was able to produce good sensitivity, at 
concentration ranges of proteins we might expect in vivo, we anticipated that 
performance could vary in response to the sensitivity and specificity of 
antibodies used, and were hence selective in the choice of the antibodies we 
used  
 


















Log [conc.] (ng/mL) 
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Figure 3.2. Recombinant c-Src was labelled with three probes (STS-2, DA-
3 and IBET-1) and a DMSO control, captured on the microarray and 
visualized with anti-c-Src Abs and a TSA Cy5 kit. Bottom to top (ng/ml): 
10,000, 1000, 100, 10, 1. Array was scanned under PMT 140. In-gel 
fluorescence scanning of the samples was analysed in a gel format (bottom 
left). 
 
We next performed spike-in experiments, to assess the potential to 
perform this capture and profiling within the context of a complex cellular 
proteome. HepG2 lysates were spiked with recombinant c-Src at varying 
concentrations (1, 10, 100, 1,000, 10,000 ng/ml). Each of these mixtures were 
treated with 3 different probes respectively (Figure 3.3A). Encouragingly, the 
results were generally consistent with those obtained with pure protein and in-
gel fluorescent scanning. Background signals were evident with DMSO at 
10,000 ng/ml c-Src spiked concentrations, due to non-specific capture of 
proteins on the array even after extentively washing. However, the background 
was negligible at lower protein target concentrations (Figure 3.3A). Both DA-3 
and STS-2 were able to capture c-Src from complex cell lysates, with signals 
diminished with decreasing quantities of spiked protein. Under a higher PMT 
to improve signal to noise, it was observed that as low as 10 ng/ml of c-Src in 
the lysate could successfully be detected with DA-3 by using the array strategy 
(Figure 3.3B). Based on the database, the concentration of endogenous c-Src 
ranged from 1 to 100 ng/ml. The sensitivity of our strategy appeared to be 
sufficient to detect the endogeous c-Src. We next compared the sensitivity of 
microarray system with that of the fluorescent gel. The sensitivity attained on 
microarrays was around 10 ng/mL, appearing to be one order of magnitude 
higher than that obtained through imaging on fluorescent gels (Figure 3.3B), 
and this is likely attributable to the TSA strategy adopted, which offered signal 
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enhancement. In addition, the spectrum of c-Src profiles in lysate screened with 
the other 6 probes remained were largely within expectations. Another kinase 
probe (IM-1) was able to capture c-Src and showed detectable signals on the 
arrays (Figure 3.4A, B). In addition, P1 a probe that was designed for PDIs, was 
capable of binding c-Src within cell lysates, while PU-1 and 16F16A presented 
weaker binding with c-Src. PD-1 and CC-1 generally did not bind c-Src, even 
at high protein concentrations.  
 
Figure 3.3. Spike-in lysate labelling and profiling. (A) HepG2 lysates (1 
mg/ml) spiked with the same concentration gradient of recombinant c-Src 
(10,000, 1,000, 100, 10, 1 ng/ml) was labelled with three probes (STS-2, 
DA-3 and IBET-1) and a DMSO control, captured on the microarray and 
visualized with anti-c-Src Abs and a TSA Cy5 kit. Bottom to top (ng/ml): 
10,000, 1000, 100, 10, 1. Array was scanned under PMT 140. In-gel 
fluorescence scanning of the samples was analysed in a gel format (bottom 
left). (B) Concentration-dependent gel and microarray results of recombinant 
c-Src labelled with DA-3. The corresponding fluorescent gel (inset) was 
imaged in the Cy3 channel. The error bars represent standard deviations 
across two independent experimental replicates. Array was scanned under 
PMT 180. 



































c-Src (ng/ml) 1,000 100 10 110,000
(A) 
(B) 





Figure 3.4. (A) Recombinant c-Src and spiked cell lysate (1, 100, 10,000 
ng/ml) are labelled with P1, IM-1, PU-1, 16F16A, CC-1 and PD-1. 
Fluorescent gel (Top) and Coomassie stain (Bottom). (B) HepG2 lysate 
samples were capture on microarry and visualized with anti-c-Src Abs and a 
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3.4 In Situ Labelling Profiling 
Having demonstrated that we could successfully adopt this strategy in 
vitro with c-Src, we went ahead to also test this approach in live cells. To 
increase the captured targets as much as possible, we used our compounds at 
high concentration (10 µM), with HepG2 cells under standard growth 
conditions. The cells were then isolated and lysed. The resulting labelled 
proteome was immobilized onto slides at optimal concentration (2 mg/ml) and 
detected against a repertoire of six antibodies. The complete array result was 
summarized as a coloured heat map (Figure 3.5). Based on these results, some 
initial conclusions could be drawn. Firstly, each antibody exhibited distinctive 
binding fingerprints, and each probe displayed unique binding affinity to 
corresponding targets. Secondly, most probes exhibited potent binding ability 
with their potential targets. For instance, PU-1 and DA-3 successfully captured 
their respective targets CDK1 and c-Src (Figure 3.5). STS-2 appeared to capture 
a range of kinases (PKA, CDK1, c-Src and MEK1), as should be expected.123 
16F16A successfully bound to its target PDI, as did P1. CC-1 consistently 
exhibited weak binding against the range of protein targets.  
 
Figure 3.5. Heatmap of nine probes against six antibodies. 
 
1 2 3 4 5 6 7 8 9 10
1 Buffer DMSO wo DMSO w NP PU-1 PD-1 DA-3 P1, 1 µM VX-1 SB-1
2 SO-1 GE-1 IM-1 CC-1 SP-1 16F16A, 1µM IBET-1 STS-2 DA-3, 1 µM P1, 1 h
3 16F16A SB-1, 1 µM IM-1, 1 µM P1 IBET-1, 1 µM DMSO, 4u P1, 4u
4 Buffer DMSO wo DMSO w NP PU-1 PD-1 DA-3
5 P1, 1 µM VX-1 SB-1 SO-1 GE-1 IM-1 CC-1 SP-1 16F16A, 1 µM IBET-1
6 STS-2 DA-3, 1 µM P1, 1h 16F16A SB-1, 1 µM IM-1, 1 µM P1 IBET-1, 1 µM DMSO, 0.25u DMSO, 0.5u
7 DMSO, 1u DMSO, 2u P1, 0.25u P1, 0.5u P1, 1u P1, 2u Buffer DMSO wo DMSO w NP
8 PU-1 PD-1 DA-3 P1, 1 µM VX-1 SB-1 SO-1 GE-1 IM-1 CC-1
9 SP-1 16F16A, 1 µM IBET-1 STS-2 DA-3, 1 µM P1, 1 h 16F16A SB-1, 1 µM IM-1, 1 µM P1
10 IBET-1, 1 µM DMSO, 4u P1, 4u Buffer
11 DMSO wo DMSO w NP PU-1 PD-1 DA-3 P1, 1 µM VX-1 SB-1 SO-1
12 GE-1 IM-1 CC-1 SP-1 16F16A, 1 µM IBET-1 STS-2 DA-3, 1 µM P1, 1h 16F16A
13 SB-1, 1 µM IM-1, 1 µM P1 IBET-1, 1µM DMSO, 0.25u DMSO, 0.5u DMSO, 1u DMSO, 2u P1, 0.25u P1, 0.5u
14 P1, 1u P1, 2u Buffer DMSO wo DMSO w NP PU-1 PD-1 DA-3 P1, 1 µM
15 VX-1 SB-1 SO-1 GE-1 IM-1 CC-1 SP-1 16F16A,1µM IBET-1 STS-2
16 DA-3, 1 µM P1, 1h 16F16A SB-1, 1 µM IM-1, 1 µM P1 IBET-1, 1 µM DMSO, 4u P1, 4u
17 Buffer DMSO wo DMSO w NP PU-1
18 PD-1 DA-3 P1, 1 µM VX-1 SB-1 SO-1 GE-1 IM-1 CC-1 SP-1
19 16F16A, 1 µM IBET-1 STS-2 DA-3, 1 µM P1, 1h 16F16A SB-1, 1 µM IM-1, 1 µM P1 IBET-1, 1 µM
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3.5 Target Validation 
 
Figure 3.6. In situ labelling with 9 probes, captured on the microarray and 
target validation (A) Microarray image of 6 probes profiling against 4 
selective antibodies (B) Pull-down result of corresponding probes for target 
validation. (C) Preliminary off-targets validation for P1 (left) and PU-1 
(right). Concentration dependent labelling of P1 and PU-1 with recombinant 
PKA. 
 
To further evaluate the accuracy of heatmap obtained from microarrays, 
in situ labelling and PD/WB target identification with 4 of the antibodies and 
six of the probes were carried out under same conditions (Figure 3.6A, B). The 
results were largely consistent, as visualized in the similar heatmap patterns. For 
instance, both STS-2 and DA-3 exhibited interactions with c-Src. This was 
consistent with spike-in experiments. Apart from c-Src, STS-2, also interacted 
with PKA and CDK1, as is characteristic of staurosporine (STS), being a broad-
spectrum kinase inhibitor. P1 and 16F16A, as the strongest PDI probes based 
on microarray results, exhibited strong interaction with PDI in PD experiment 
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while the rest of the probes consistently showed weak binding to PDI, 
confirming the microarray result. In addition, P1 also exhibited interactions 
with various kinases including PKA, c-Src and CDK1. P1 displayed a much 
wider spectrum of interactions than initially expected, potentially due to its 
electrophilic phenyl vinyl sulfonate. Similarly, the results of PD-1 and PU-1 
from WB matched those from microarray. In particular, PD-1 bound CDK1. 
PU-1 as a probe for CDK1, exhibited binding interactions with PKA and c-Src 
as well. With these preliminary results, we picked up both ABP (P1) and AfBP 
(PU-1) for further validation. As for P1, in vitro concentration dependent 
labelling of recombinant PKA was carried out. As shown in Figure 3.6C, P1 
was able to label PKA, with signals detectable even at low concentrations of 0.1 
μM, suggesting strong interactions between P1 and PKA. Similarly, PU-1 
bound with recombinant PKA at a low concentration of 0.2 µM (Figure 3.6C).  
3.6 Conclusion 
 In conclusion, we have developed the first microarray-based platform 
to our knowledge, capable of rapidly identifying on- and off-targets of drug-like 
compounds from live cells. Compared to gel-based scans and WB, microarrays 
consume less samples but can sensitively detect endogenous proteins. In this 
work, we have successfully profiled a panel of drug-like ABP and AfBP 
bioactive compounds against various protein targets, and have likely identified 
the off-targets of ABP (P1) and AfBP (PU-1). It should be highlighted that the 
quality of the antibodies used are critical to ensure robust interpretations of only 
the target proteins in the array. Overall, this microarray-based strategy would 
enhance and complement high-content screening approaches, for early stage 
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lead-optimization, and off-target screening, in drug discovery applications. A 
single experiment thus performed on a microarray slide could replace dozens of 
WBs/PDs, and consequently, accelerate target profiling.  




Intracellular Delivery of Functional Proteins 





The efficient delivery of bioactive compounds into cells is a major 
challenge in drug discovery. This chapter summarized the development of novel 
methods for intracellular delivery of functional proteins (including antibodies) 
and native small molecule drugs by making use of cell-penetrating 
poly(disulfide)s, or CPDs. CPDs were recently shown to be rapidly taken up by 
mammalian cells in endocytosis-independent pathways, but their applications 
for delivery of proteins and native small molecule drugs have not been 
demonstrated. With our newly developed, CPD-assisted approaches, rapid and 
“bioorthogonal” loading of cargos was carried out with pre-synthesized CPDs, 
in two-steps and in a matter of minutes under aqueous conditions. The resulting 
CPD-cargo conjugates were used immediately for subsequent cell delivery 
studies. With the versatility and flexibility of these methods, we further showed 
they could be used for immediate delivery of a variety of functional cargos with 
minimum chemical and genetic manipulations. The minimal cell cytotoxicity of 
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these CPDs and their cargo-loaded conjugates further highlights the unique 
advantage of this new cell-transduction method over other existing strategies, 
and ensures our entire delivery protocol is compatible with subsequent live cell 
experiments and biological studies. 
4.1 Introduction 
The efficient delivery of bioactive compounds, including nucleic acids, 
peptides/proteins and small molecules, into cells is a major challenge in drug 
discovery.124 The difficulty is more pronounced for large molecules such as 
proteins and DNAs/RNAs,125-130 but due to the hydrophobicity and poor water 
solubility of many small molecule drug candidates, such compounds don’t enter 
cells readily either, without proper formulation and/or delivery ve-hicles.131-133 
To achieve intracellular delivery of proteins, a variety of methods have been 
developed in the last 20 years, including the use of cell-penetrating peptides 
(CPPs), super-charged proteins, liposomes, nanoparticles (NPs) and 
polymers.134-141 Despite significant progress, these methods have their share of 
shortcomings, including low/variable delivery efficiency, the need for protein 
modification, high cytotoxicity, and perhaps most importantly, ineffective 
endosomal/lysosomal escape.130 Take CPPs for example, it is well-documented 
that, while CPP-conjugated small- and medium-size cargos may be efficiently 
transduced into cells via non-endocytic pathways, large cargos such as proteins 
are mostly taken up by endocytosis, leading to subsequent endosomal trapping 
and lysosomal degradation.142,143 To deliver hydrophobic small molecules 
intracellularly, chemical modifications may be used to make analogs that 
possess improved physicochemical and pharmacokinetic profiles,144 but this is 
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costly, time-consuming and worse, often results in alteration of the compound’s 
biological properties.3b Recent ad-vances in material chemistry have provided 
alternatives, where native drugs are directly “loaded” into a suitable “container” 
without the need of chemical modifica-tions.133,145-147 For example, the use of 
small molecule-encapsulated mesoporous silica nanoparticles (MSNs) for drug 
delivery is worth-noting, in part due to the numerous desirable properties that 
MSNs possess, including high loading capacity, biocompatibility and “zero 
premature release”.145,146 In order to minimize unwanted leakage of the 
encapsulated drug and improve cellular uptake of MSNs, the surfaces of these 
nanoparticles are “capped” with CPPs and other forms of chemicals,148-150 
which, in most cases, also leads to severe endosome trapping and ineffective 
drug release.148,149 
Herein, we focus on the development of novel methods for intracellular delivery 
of functional proteins (including antibodies) and native small molecule drugs 
by making use of cell-penetrating poly(disulfide)s, or CPDs (Figure 4.1A).151-
154 CPDs could be considered synthetic mimics of poly-arginine CPPs, in which 
the polypeptide backbone was replaced with poly(disulfide)s. Upon cellular 
uptake, CPDs are rapidly degraded in the cytosol by glutathione (GSH)-assisted 
depolymerization and show minimal cytotoxicity.151-156 Importantly, Matile et 
al showed in a recent study that, CPDs made of thiol-modified small 
fluorophores (as initiators/cargos), a guanidinium propagating monomer (e.g. 
M in Figure 4.1A) and a terminator (e.g. T), rapidly enter mammalian cells via 
thiol-mediated pathways.152 The major issue of endosomal trapping commonly 
associated with CPPs and other means of delivery was thus minimized.154 
Subsequently, the authors proposed this substrate-initiated, cell-penetrating 
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poly-(disulfide)s (siCPDs) may be used for intracellular delivery of other thiol-
containing (or modified) cargos. This hypothesis was, however, never 
demonstrated experimentally. Furthermore, during siCPD synthesis, given the 
obligatory role of the thiol-containing initiator (I), the need of millimolar 
concentrations of initiator/monomer/terminator as well as organic co-solvents, 
it is not trivial how a protein could be directly used as an initiator , nor is it  
  
Figure 4.1. Overview of CPD-facilitated intracellular delivery of proteins 
(including antibodies) and native small molecule drugs.157 (A) Newly 
developed initiators (I1/I2/I3), Monomer (M), terminator (T), the 
polymerization/depolymerization process of CPDs, and the two-step 
approach for “conjugation” of protein cargos with CPDs. (B) Summary of 
non-covalent and covalent approaches for bioorthogonal attachment of CPDs 
to proteins. The highly efficient site-specific tetrazine-TCO ligation reaction 
is highlighted. (C) Schematic summary of intracellular delivery of native 
small molecules by drug-loaded MSNs capped with BiotinCPD. (D) Table 
summary of all CPDs and cargos used in the current study. 
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practical to use thiol-modified small molecule drugs, as few small molecule 
drugs contain native thiols in their structures.     
With the current work, we have confirmed that, for the first time, 
proteins conjugated with CPDs, either covalently (via bioorthogonal chemistry) 
or non-covalently (via affinity interaction), could be rapidly and efficiently 
delivered into the cytosol of different mammalian cells without being trapped 
by endocytic vesicles. Similarly, by making use of CPD-capped MSNs, we have 
successfully achieved intracellular delivery of native small molecule drugs (e.g. 
doxorubicin, or Dox). Our results indicate these novel protein and small 
molecule delivery methods possess the following favorable properties when 
compared to most existing strategies: (1) fast delivery, with cell entry in less 
than 15 min, (2) flexible, enabling convenient delivery of different types of 
cargos, (3) less cytotoxic and applicable to different types of mammalian cells, 
(4) efficient, facilitating cargo delivery at nanomolar concentrations, and (5) 
immediately available upon cell entry due to rapid CPD degradation, thus 
retaining the biological activity of the delivered cargo.  
4.2 Design and Synthesis of New CPDs. 
We were intrigued by the excellent properties of siCPDs (e.g. minimal 
endosome trapping and cytotoxicity), as reported by Matile et al,151-153,156 and 
wondered whether robust, CPD-mediated methods could be developed to 
facilitate intracellular delivery of functional proteins, therapeutic antibodies and 
native small molecule drugs (that is, without any form of thiol modification). 
Instead of the substrate-initiated CPD synthesis as originally proposed,152 we 
envisaged such cargos could be more conveniently appended, in two steps, to 
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pre-synthesized, functionally decorated CPDs by using suitable “conjugation” 
chemistries that are already available for recombinant proteins/antibodies and 
small molecules (Figure 4.1). Three types of thiol-containing initiators, 
I1/I2/I3, were thus designed, containing biotin, nitrilotriacetic acid (NTA) and 
tetrazine (Tz), respectively. Upon polymerization, the corresponding CPDs 
(BiotinCPD, Ni-NTACPD & TzCPD; Figure 4.1D), could be obtained. Ni-NTACPD 
could be attached bioorthogonally to readily available (His)6-tagged proteins via 
non-covalent affinity interaction (KD of Ni-NTA/(His)6 < 10
-7 M). BiotinCPD 
was designed to test whether it could be used to deliver avidin via similar non-
covalent, but substantially stronger, interaction (KD of biotin/avidin < 10
-15 M). 
For a therapeutic antibody (Ab), which might not possess a his-tag,158 we used 
the well-known bis-sulfone chemistry that enables site-specific introduction of 
a trans-cyclooctyne (TCO) into the native disulfide present in the antibody (vide 
infra).159 Subsequent bioorthogonal covalent attachment of TzCPD to the TCO-
modified antibody would result in quantitative formation of CPD-Ab within 
minutes by the highly efficient tetrazine-TCO ligation (Figure 4.1B).160 To 
“append” a native small molecule drug to the CPD, we would use a positively 
charged CPD (BiotinCPD in this case) to cap the negatively charged, drug-loaded 
MSNs (i.e. MSN-Dox) by electrostatic interaction, giving CPD-MSN-Dox 
(Figure 4.1C-D); the capping of nanoparticles with CPDs is unprecedented and 
we were hopeful that, if CPDs could facilitate endocytosis-independent cellular 
uptake of large, nanometer-size cargos such as MSNs, then a variety of 
hydrophobic drugs could potentially be delivered intracellularly in their native 
form, in a controllable manner.145-147    
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All three initiators were conveniently synthesized (two of which in their 
respective disulfide forms; Scheme 4.1), and treated/reduced with TECP 
immediately prior to polymerization. The monomer (M), as well as subsequent 
polymerized products with the corresponding initiators (and capped with T; 
Figure 4.1A), were synthesized according to published protocols.152  
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Scheme 4.1. Initiators synthesis.157 (a) EDC.HCl, cystamine 
dihydrochloride, trimethylamine, DMF, 18 h, r.t., 91%; (b) TCEP, 50% 
DMF/H2O, 30 min, r.t.; (c) EDC
.HCl, cystamine dihydrochloride, 
trimethylamine, DMF, overnight, r.t., 91%; (d) TCEP, 50% DMF/H2O, 30 
min, r.t. ; (e) Bromoacetic acid, 2 M aqueous NaOH, 2 h, r.t., then 19 h, 50 
°C, 80%; (f) H2, Pd/C, MeOH, 12 h, r.t., 75%; (g) 4-butyrothiolactone, 
NaHCO3, 72 °C, 15 h, 70%; (h) CDI, ethylene diamine, DCM, 2 h, r.t., 78%; 
(i) 1H-pyrazole-1-carboxamidine hydrochloride, DCM, 4 h, r.t., 56%. r.t. = 
room temperature 
 
Upon purification, the resulting CPDs were further characterized by gel 
permeation chromatography (GPC), giving an average molecular weight (Mw) 
of 22-32 KDa with a polydispersity index (PDI) of 1.5-2.3 (Figure 4.1D & 
4.2A). The concentration of TzCPD stock solution was determined by 
measurement with UV-Vis spectroscopy at the tetrazine absorbance (520 nm),161 
and for the other two CPDs, they were similarly estimated.  
Figure 4.2. Polymer synthesis and characterization.157 (A) Representative 
GPC profiling of polymers (1) BiotinCPD, (2) TzCPD, (3) NTACPD. (B) 
Polymer depolymerization tested by fluorescent in-gel scanning. 10 nM 
CPD-Avidin (treated without and with GSH (10 mM) or HeLa lysate (1 
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mg/ml) for 1 h at 37 oC before SDS-PAGE (DTT-free) and in-gel 
fluorescence scanning. AvidinCy5 (CPD-free) was used as negative control. 
(C) UV-Vis measurement of TzCPD concentration using tetrazine disulfide 
(3) of different concentrations (50, 100, 200, 400, 500 µM) to generate 
standard curve (y = 2.03 x -0.0014, R2 = 0.998). The TzCPD concentration 
of obtained stock was 200 μM. 
4.3 Protein Attachment to CPDs.  
We next chose three fluorescently labeled recombinant proteins having 
different molecular weights, AvidinCy5 (~80 KDa in its tetrameric form), TCO-
BSACy5 (~66 KDa) and BRD-4Cy5 (~15 KDa; an epigenetic reader protein19) as 
model cargos for delivery by BiotinCPD, TzCPD and Ni-NTACPD, respectively. 
Fluorescent labeling of these proteins was done by standard protein conjugation 
chemistry with commercially available Cy5 dyes (Figure 4.3), thus allowing the 
entire cargo delivery process to be monitored by fluorescence microscopy and 
quantified by flow cytometry. Attachment of CPDs, either non-covalently or 
covalently, to the proteins was next done by simple “mix-and-go” protocols, 
giving CPD-Avidin, CPD-BSA and CPD-BRD-4, respectively (Figures 4.4). 
It should be highlighted that our choices of highly bioorthogonal “conjugation” 
chemistries between CPDs and proteins were critical, not only for convenient 
sake and generality, but more importantly to allow protein complexes be 
directly used in subsequent cell-based experiments. Furthermore, since most 
CPD/protein-complexing reactions couldn’t be reliably monitored by SDS-
PAGE without addition of DTT, which in turn caused CPD degradation (data 
not shown), we needed such conjugation chemistries to be free of failure! 
Nevertheless, we found that, for AvidinCy5 and CPD-Avidin, they were well 
separated under modified DTT-free SDS-PAGE conditions (presumably due to 
extremely strong biotin/avidin interaction and avidin stability162), and were thus 
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chosen as the model system to monitor the processes of CPD/protein complex 
formation and GSH-assisted intracellular depolymerization/cargo release 
(Figure 4.2B); upon incubation with a freshly prepared HeLa lysate (1 mg/mL) 
for 1 h at 37 oC, the higher-order CPD-Avidin complex was found to have 
significantly depolymerized, indicating our CPD-loaded protein cargos would 
also be released readily in cytosolic environments.  
  
Figure 4.3. Labeling process of avidin, BRD-4, BSA and AbFC.157 (A) 
Recombinant avidin was labeled with Cy5-NHS to generate AvidinCy5. (B) 
Recombinant (His)6-tagged BRD-4 was labeled with Cy5-NHS to generate 
BRD-4Cy5. (C) Recombinant BSA was first labeled with TCO via site-
specific conjugation between TCO-PEG3-Maleimide and the single free 
cysteine present in the protein. Next, TCO-BSA was fluorescently labeled 
with Cy5-NHS to obtain TCO-BSACy5. (D) For antibody conjugation, a 
commercially available FC-labeled antibody (i.e. AbFC) was used, and the 
TCO moiety was site-specifically introduced to the antibody by first 
reducing the disulfide bond linkage in the antibody, followed by treatment 









Figure 4.4. Formation of CPD-Protein and CPD-MSN-Dox.157 (A) The 
formation of CPD-BSA between TzCPD and TCO-BSACy5, and CPD-Ab 
between TzCPD and TCO-AbFC, via TCO-tetrazine bioorthogonal ligation. 
(B) Non-covalent formation of CPD-Avidin between BiotinCPD and 
AvidinCy5, CPD-BRD-4 between Ni-NTACPD and BRD-4Cy5, and CPD-
Casp-3 between Ni-NTACPD and (His)6-tagged caspase-3, via affinity 
interaction. (C) “Capping” of small molecule drug-loaded MSNs with CPD 
via electrostatic charge-charge interaction between the negatively charged 
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4.4 Cellular Uptake.  
 
Figure 4.5. Cellular uptake of CPD-conjugated proteins.157 (A) Real-time 
CLSM of live HeLa cells treated with 50 nM of CPD-BSA (red), 
LysoTracker™ (green) and Hoechst (blue) at indicated time intervals. (Inset) 
bright-field images of the corresponding fluorescence channels. Scale bar = 
20 µm. (B) 3D projections of z-stack images (left to right: different 
perspectives) of live HeLa cells treated with 50 nM CPD-BSA for 15, 30, 
60, 120 and 240 min (step size, 0.186 µm). Cells were co-stained with 
Hoechst and LysoTrackerTM for 15 min at 37 oC prior to the termination of 
protein delivery. 
 
In order to unequivocally demonstrate the cellular uptake of the CPD-
conjugated proteins, and their subcellular localization, we used confocal laser 
scanning microscopy (CLSM) with live HeLa cells. It was previously found that 
the use of fixed cells are not suitable for such studies;142 upon fixation, cargos 
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delivered by CPPs and other means often artificially “escape” from endocytic 
vesicles, thus resulting in misleading conclusions.130,163,164 Real-time imaging 
experiments together with different fluorescence organelle trackers 
(CellMask™ membrane tracker/LysoTracker™: pseudocolored in green; 
Hoechst nuclear stain: pseudocolored in blue) were carried out. As shown in 
Figure 4.5A, 2 min upon addition of 50 nM of CPD-BSA (pseudocolored in 
red) to the culture medium at 37 oC, green fluorescence started to accumulate 
around the cell membrane. After 15 min, a substantial amount of CPD-BSA was 
observed to have successfully been transduced and evenly distributed 
throughout the cytosolic space, with no evidence of endosome/lysosome 
trapping. This trend persisted for the next 2 h (Figures 4.5B). With prolonged 
incubation (> 4 h), however, we started to observe some merged green/red 
fluorescence signals, indicating some delivered protein had been destined for 
lysosomal degradation, presumably due to high protein concentration or 
unfolding.130 
We next directly compared the cellular uptake efficiency of this 
CPD-assisted strategy with that of the Pro-JectTM reagent, a commercially 
available liposome-based protein delivery system.79 In addition to CLSM 
(Figure 4.6A), we analyzed the successfully delivered and depolymerized 
proteins by SDS-PAGE/in-gel fluorescence scanning of lysates from treated 
cells (Figure 4.6C). We further quantified protein uptake by flow cytometry 
analysis (Figure 4.6C). In order to minimize false readings of cells derived 
from membrane-bound, but not internalized, fluorescent proteins, cells were 
washed with heparin-containing PBS before analysis.152 In all cases, with all 
three protein cargos (TCO-BSACy5, AvidinCy5 & BRD-4Cy5) having 
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different types of “conjugation” chemistries (covalent and non-covalent), 
their resulting CPD-complexes (CPD-BSA, CPD-Avidin & CPD-BRD-4) 
were delivered into HeLa cells more efficiently than the Pro-Ject™ delivery 
method. Successful intracellular uptake of a cargo was found to be 
completely dependent on its complex formation with the corresponding 
CPD, as none of the cargos alone (Figure 4.6A-B) could enter cells. We 
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Figure 4.6. Comparison of the delivery efficiency of CPDs versus Pro-
JectTM.157 (A) Confocal image of HeLa cells treated with 50 nM CPD-
Protein or 50 nM proteinCy5/Pro-JectTM complex for 1 h. Cells were co-
stained with Hoechst and CellMaskTM after delivery (red, CPD-Protein, λex 
= 643 nm, λem = 665-740 nm; green, CellMaskTM, λex = 543 nm, λem = 555-
650 nm; blue, Hoechst, λex = 405 nm, λem = 440-470 nm). (1) 50 nM TCO-
BSACy5, (2) 50 nM CPD-BSA, (3) 50 nM TCO-BSACy5 + Pro-JectTM, (4) 50 
nM AvidinCy5, (5) 50 nM CPD-BSA, (6) 50 nM AvidinCy5 + Pro-JectTM, (7) 
50 nM BRD-4Cy5, (8) 50 nM CPD-BRD-4, (9) 50 nM BRD-4Cy5 + Pro-
JectTM. (Insert) Bright-field images of the corresponding fluorescence 
channels. Scale bar = 20 μm. (B) Comparison of the delivery efficiency of 
CPDs versus Pro-JectTM measured with FACS (green) and HCS (blue). HeLa 
cells were incubated with 50 nM CPD-Protein complex or 50 nM 
proteinCy5/Pro-JectTM for 1 h before Hoechst stained, imaged and sorted 
(CPD-Protein, λex = 632 ± 22 nm, λem = 684 ± 25 nm; Hoechst, λex = 390 ± 
18 nm, λem = 432.5 ± 48 nm). (1) CPD-BSA, (2) CPD-Avidin, (3) CPD-
BRD-4. (C) In-gel fluorescence scanning and coomassie gel of 
corresponding HeLa lysates. (1) CPD-BSA, (2) CPD-Avidin, (3) CPD-
BRD-4. (Lanes): 1. Blank; 2. proteinCy5 in DMEM; 3. proteinCy5 in serum-
free DMEM; 4. CPD-Protein; 5. proteinCy5 + Pro-JectTM. Each set of data 
was independently normalized to HeLa treated with CPD-Protein at 37 oC 
(set to 100) and HeLa treated with proteinCy5 at 37 oC (set to 0).  
 
of electrostatic/hydrophobic interaction for complex formation with a target 
protein (thus delivery efficiency varies significantly with protein size/charge; 
see Figures 4.6B-C),79 proteins of different sizes and charges were efficiently 
delivered by the CPD-assisted method. Gratifyingly, even (His)6-tagged 
proteins formed by comparatively moderate non-covalent interaction with Ni-
NTACPD (e.g. CPD-BRD-4) could be delivered, thus setting the stage for more 










































Figure 4.7. Comparison of the cytotoxicity of CPDs versus Pro-JectTM.157 
Cell viability measured with XTT assay for HeLa cells treated with a protein 
(50 nM; 1 h incubation) delivered by either CPD or Pro-JectTM method. 
buffer-treated cells were used for normalization (as 100% viability). 
 
In addition, we found the CPD method was significantly less cytotoxic 
than the Pro-Ject™ approach for protein delivery (Figure 4.7). This is in good 
agreement with previous cell-based experiments with fluorophore-loaded 
siCPDs.152 In fact, the 10-20% cell death observed in our experiments was likely 
caused by trace amount of residual iodoacetamide from the polymerization 
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Figure 4.8. Time- and concentration-dependent delivery of CPD-protein.157 
Time-dependent delivery of (1) CPD-BSA, (2) CPD-Avidin and (3) CPD-
BRD-4 with HeLa Cells as measured by FACS (green) and HCS (blue). 
Concentration-dependent delivery of (4) CPD-BSA, (5) CPD-Avidin and 
(6) CPD-BRD-4 with HeLa cells as measured by FACS (green), HCS (blue). 
For concentration-dependent experiment, HeLa cells were incubated with 
CPD-Protein (5, 10, 50 and 100 nM) for 8 h, followed by Hoechst stained, 
imaged and sorted. For time-dependent experiment, HeLa cells were 
incubated with 50 nM CPD-Protein for 15, 30, 60, 120, 240, and 480 min 
before imaged and sorted. Co-staining was done with Hoechst 15 min prior 
to the termination of protein delivery. (CPD-Protein, λex = 632 ± 22 nm, λem 
= 684 ± 25 nm; Hoechst, λex = 390 ± 18 nm, λem = 432.5 ± 48 nm).  
 
Further optimizations of CPD-Protein delivery were done by 
concentration- and time-dependent experiments (Figures 4.8). In addition to 
flow cytometry, we used imaging-based, high-content screening (HCS) for 
comparative studies. HCS could be used to simultaneously analyze many live 
cells in the same experiment, without cell detachment/fixation which might 
cause artifacts, thus was a quantitative complement to our CLSM results. As 
expected, both longer incubation time and higher cargo loading led to increases 
in the amount of delivered proteins. With the issues of potential lysosomal 
degradation and cytotoxicity in mind, we recommend the optimal conditions for 
this CPD delivery method to be 25-50 nM protein loading and 1-2 h incubation, 
which are still more efficient than existing protein delivery strategies.134-141 
PC3 MCF7 NIH313 A549 HeLa
0
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Figure 4.9. CPD delivery in different mammalian cells.157 Quantification of 
cellular uptake efficiency of different cell lines (PC3, MCF-7, NIH 3T3, 
A549, HeLa) as calculated by HCS. Cells were incubated with 50 nM of 
CPD-BSA (red; CPD-BSA, λex = 632 ± 22 nm, λem = 684 ± 25 nm) for 1 h 
before being imaged/quantified by In-Cell Analyzer. 
 
The CPD method was further tested on other mammalian cell lines (NIH 
3T3, MCF-7, A549 and PC3; Figure 4.9); in all cases, CPD-BSA was 
successfully taken up intracellularly, albeit at varying degrees of efficiency.   
 
Figure 4.10. Temperature and endosome inhibition assay.157 (A) 
Temperature-dependent protein uptake by HeLa cells (50 nM protein; 1 h 
treatment), as determined by flow cytometry. Data were normalized to those 
obtained at 37 oC. (Inset) SDS-PAGE/in-gel fluorescence scanning of lysates 
from treated cells. (B) Flow cytometry/HCS quantification of  protein uptake 
(50 nM of CPD-BSA; 1 h incubation) by HeLa cells treated with different 
inhibitors, including chlorpromazine (CPZ), wortmannin (w), methyl-β-
cyclodextrin (MβCD) and 5,5’-dithioobis-2-nitrobenzoic acid (DTNB). Data 
were normalized to those of HeLa cells treated with CPD-BSA only (Blank). 
 
Our earlier CLSM results showed even cytosolic distribution of 
intracellular fluorescence upon protein delivery (Figure 4.5-4.6), indicative of 
endocytosis-independent pathways facilitated by these CPDs as previously 
proposed.152 In order to further confirm this, we carried our detailed uptake 
studies of CPD-Protein by HeLa cells at different temperatures and in the 
presence of endocytosis inhibitors. In general, cell uptake profiles observed with 
these CPD-conjugated proteins were similar to what was previously reported 
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with small fluorophore-modified siCPDs.152 Reduced temperature decreased 
protein delivery efficiency but did not block the process completely (Figure 4.10 
A). Low temperature might decrease the fluidity of the bilayer membrane and 
thus affected the transduction efficiency. The insensitivity of protein delivery 
with endocytosis-related inhibitors used (chlorpromazine, wortmannin & 
methyl-β-cyclodextrin), ruled out the endocytosis pathway. On the contrary, 
blocking exofacial thiols on the cell surface with 5,5’-dithiobis-2-nitrobenzoic 
acid (DTNB) significantly suppressed protein uptake, further supporting thiol-
mediated cargo delivery mechanisms.152 During this process, CPDs would first 
accumulated on membranes via counter-ion interaction and then covalently 
bond to exo-facial thiol facilitating the formation of micellar pores.  Finally, 
proteins crossed the membrane through micellar pores. In our hands, flow 
cytometry gave less consistent results, presumably due to non-specific, surface-
bound CPD-Protein and the need of cell detachment (Figure 4.10B). HCS on 
the other hand, was more reliable, enabling direct quantification of live cells 
having only intracellular fluorescence signals. 
4.5 CPD-Assisted Transduction of Functionally Active 
Caspase-3 
Having confirmed the effect of this newly developed CPD method for 
intracellular protein delivery with minimal endosome trapping, we next 
investigated whether it could deliver functional, therapeutic proteins. Caspase-
3 (a cysteine protease) is a promising therapeutic protein owing to its key role 
in cell apoptosis.165 Intracellular delivery of active caspase-3 to tumor cells 
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render them hypersensitive toward treatment by anticancer drugs such as 
Dox.166 Functionally active, recombinant (His)6-tagged caspase-3 was prepared 
as previously described.167 Upon mixing with Ni-NTACPD, the resulting CPD-
Casp-3 was formed. Mindful of the trace amount of iodoacetamide from CPD 
preparation, and that absence of DTT might further reduce the enzymatic 
activity of caspase-3,167 we carried out normalization of CPD-Casp-3 (Figure 
4.11); results indicate that even without DTT, CPD-Casp-3 was able to retain 
> 20% of the original caspase-3 activity. The activity of the complex was 
partially restored upon DTT treatment, presumably due to either CPD 
depolymerization or/and DTT reduction of active-site cysteine in the enzyme. 
Therefore for CPD-Casp-3, upon cell entry, its enzymatic activity would also 
be restored under the highly reduced cytosolic environment.  
 
Figure 4.11. Enzymatic assay of CPD-Casp-3 in HEPES buffer or DTT-free 
HEPES buffer.157 5 μM active caspase-3 was incubated with 15 μM Ni-
NTACPD in HEPES buffer (10 mM HEPES, pH = 7.9) for 15 min on ice to 
form the CPD-Casp-3 complex.  Subsequently, 50 pM of CPD-Casp-3 was 
incubated with 1 μM Ac-DEVD-AMC in HEPES buffer at 25 oC. Activity of 
50 pM native (His)6-tagged caspase-3 was measured concurrently as positive 
control. HEPES buffer with substrate only was used as negative control.  
 
HeLa cells were incubated with 50 nM of CPD-Casp-3, and the 
resulting cells were imaged for intracellular caspase-3 activity upon treatment 
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with Ac-DEVD-AMC (Figure 4.12A) for 2 h;168,169 significant fluorescence 
signals (from the liberated AMC dye) throughout the cytosol of CPD-Casp-3-
treated cells, but not in control cells, were detected, indicating successful 
cytosolic delivery of the functionally active protein. These results were further 
confirmed by in vitro enzymatic determination of caspase-3 activity, as well as 
Western blotting (WB) analysis, of the corresponding cell lysates (Figure 
4.12B);150,170 in all cases, the presence of intracellular caspase-3 and its activity 
were unequivocally established. Intracellular activation of caspase-3 is known 
to promote subsequent translocation of the active enzyme into nucleus, cleave 
PARP1, and finally cause cell death by apoptosis.171 We observed similar 
phenomena in our “artificially” induced apoptotic cells as well (Figure 4.12B 
inset & Figure 4.12C). These results further suggest that cytosolic proteins 
delivered by this CPD system are not necessarily confined to their original 
destination upon cell entry. Instead, they may be further sorted/translocated in 
manners similar to endogenous proteins. 




Figure 4.12. CPD-assisted delivery of functionally active caspase-3 to HeLa 
cells.157 (A) CLSM images of HeLa cells treated with CPD-Casp-3 (50 nM) 
for 2 h, followed by incubation with Ac-DEVD-AMC (40 µM; 2 h). Scale 
bar = 20 µm. (Inset) bright-field images. (B) RFU of in vitro enzymatic 
caspase-3 assay of treated HeLa lysates.150,170 (Inset) WB results of delivered 
active caspase-3 and cleaved endogenous PARP1 in HeLa lysates from the 
same cells. (C) Cell viability/apoptosis caused by delivered active caspase-3 
as measured by XTT assay. Since it took some time for intracellular caspase-
3 to be translocated into the nucleus and cleave PARP1,79 for (B & C), HeLa 
cells were treated with CPD-Casp-3 for 8 h prior to analysis.  
 
4.6 CPD-Assisted Antibody Delivery. 
Monoclonal antibodies (mAbs) constitute one of the largest classes of 
therapeutic proteins.172 There are currently more than 30 antibody-based, FDA-
approved drugs, most of which target cancer. The number could have been 
much higher, had an effective means for intracellular delivery of antibodies 
been available.158 Common protein delivery methods are even more problematic 
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Realizing the highly efficient, endosome-independent features endowed by our 
newly developed CPD protein delivery method, we anticipated it might be 
ideally suited for delivery of therapeutic antibodies, for which many robust 
conjugation chemistries are already available in the forms of antibody-drug 
conjugates (ADCs) and PEGylation without compromising antibodies’ activity 
and stability.158,159,173,174 We used Alexa Fluor® 488 goat anti-rabbit IgG (AbFC) 
as a model antibody and modified it with a commercially available bis-sulfone 
reagent, ThioLinker-TCO™ (Figure 4.13A); upon TCEP reduction of inter-
chain disulfides in the antibody, the TCO reagent underwent double 
elimination-addition reactions with two cysteines from the same reduced 
disulfide to form a three-carbon bridge, thus successfully introducing TCO into 
the antibody while leaving it structurally intake. The same approach has been 
used for site-specific PEGylation and ADCs in various therapeutic 
proteins/antibodies.173,175 As shown in Figure 4.13B, while AbFC showed up on 
a DTT-free SDS-PAGE gel as a 250-KDa fluorescent band under the FITC 
channel (Lanes 4), successful introduction of the TCO moiety (giving the 
resulting TCO-AbFC) followed by ligation with a tetrazine-containing 
tetraethylrhodamine reporter (TER-Tz2161) shifted the band to higher 
molecular-weight regions where they became detectable under both FITC and 
TER channels (Lanes 2).  
With TCO-AbFC being successfully prepared, we next conjugated it to 
TzCPD. as earlier described, to generate CPD-Ab which was subsequently used 
for confirmation of successful intracellular antibody delivery by CLSM. As 
shown in Figure 4.13C, live HeLa cells treated with 50 nM of CPD-Ab for 1 h 
- 79 - 
 
 
were shown to have taken up the fluorescently labeled antibody and distributed 
it throughout the cytosol (right panel), whereas no fluorescence was detected in 
cells treated with the antibody alone (without conjugation to TzCPD; left panel). 
We thus conclude that this CPD-assisted method could be used for intracellular 
delivery of antibodies as well.     
 
Figure 4.13. CPD-assisted antibody delivery.157 (A) Labeling mechanism of 
antibodies by ThioLinker-TCOTM. (B) TCO-AbFC reacting with or without 
TER-Tz2, before being analyzed by SDS-PAGE (with or without 10 mM 
DTT in the loading dye). The gel was visualized under both FITC and TER 
channels. (C) HeLa cells treated with 50 nM of CPD-Ab (1 h at 37 oC) before 
being imaged. CPD-Ab (green); Hoechst (blue). Scale bar = 20 μm. 
 
4.7 Small Molecule Drug Delivery by CPD-MSNs 
 Delivery of small molecule drugs to tumor sites often suffers from low 
efficiency due to hydrophobicity and poor water solubility. Approximately 40% 
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as being poorly water-soluble.132 We reasoned the siCPD method previously 
proposed by Matile et al would have been impractical, as it would require 
chemical modification of small molecules with a thiol handle which is not 
available in most native drugs.152 We therefore turned to mesoporous silica 
nanoparticles (MSNs), which are widely used for intracellular delivery of native 
small molecule drugs. Due to the large size of MSNs (> 100 nm in diameter), 
they are often not efficiently taken up by cells unless surface modification with 
CPPs or other chemicals is introduced.145-150 In most cases, however, this leads 
to endocytosis and poor cytosolic release of MSN-encapsulated drugs. We 
wondered whether the unique endocytosis-independent mechanisms of the 
CPD-assisted delivery could be successfully emulated in drug-loaded MSNs, 
e.g. CPD-MSN-Dox.  
To make CPD-MSN-Dox, PO4
--modified MSNs were first prepared 
according to published protocols.176 Such MSNs, due to their negatively 
charged surface, were known to be minimally taken up by mammalian cells. To 
follow the cellular uptake of MSNs, they were first doped with a small amount 
of fluorescein.150 We next loaded Dox followed by capping the surface of the 
resulting drug-loaded MSNs with positively charged BiotinCPD via charge-
charge interaction. The resulting MSNs were shown to be highly monodisperse 
(mean diameter: ca. 155 nm) and possess well-defined pore sizes with high 
specific areas (Figure 4.14-4.17). Reversal of Zeta potentials from negatives in 
the PO4
--modified MSNs to positives in the CPD-capped MSNs was evident 
(Figure 4.18). In vitro GSH-induced depolymerization/uncapping followed by 
release of Dox was successfully observed (Figure 4.19).  




Figure 4.14. TEM (left) and SEM (right) images of CPD-MSN.157 The 
resulting porous silica nanoparticle is about 120 nm in diameter and arranged 
pore structure can be observed. 
 
 
Figure 4.15. Hydrodynamic size distributions of CPD-MSN in PBS buffer 
(pH = 7.4).157 The diameter of the CPD-MSN in the buffer is about 155 nm. 
 
 
Figure 4.16. BET nitrogen adsorption/desorption isotherms (A) and BJH 
pore size distribution (B) of the nanoparticles. BET specific surface values, 
pore volumes, and pore sizes calculated from the nitrogen adsorption-
desorption isotherms were 674.8 m2/g, 0.320 cm3/g, 2.45 nm for MSN-PO4
-
157 
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Figure 4.17. Powder X-ray diffraction pattern of the particles.157
 
Figure 4.18. Zeta potentials of MSN-PO4
- capped with BiotinCPD of different 
concentrations (1 to 6 represented 0, 10, 20, 50, 100 and 150 µM BiotinCPD 
respectively).157 
 
Figure 4.19. The percentage of Dox released from CPD-MSN-Dox (0.1 
mg/mL) versus the incubation time in PBS with or without 10 mM GSH.157 
 
To follow the entire process, from cellular uptake of CPD-MSN-Dox in 
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cytosolic release of Dox, we directly added to cell medium 20 µg/mL of the 
drug-loaded MSNs and the resulting cells were imaged over 24 h by CLSM, 
followed by WB and apoptosis analysis (Figure 4.20). MSN-Dox, the drug-
loaded nanoparticles without capping with BiotinCPD, was used as a negative 
control. Since Dox is an intrinsically fluorescent compound, its intracellular 
distribution could be conveniently monitored by CLSM. It is also one of the 
most effective anti-cancer drugs. By intercalating to nuclear DNA of target 
tumors, it is known to cause caspase-3 activation, PARP1 cleavage and cell 
apoptosis.177 As shown in Figure 5A, we observed accumulation of most CPD-
MSN-Dox inside the cytosol of treated cells after only 3 h of incubation, at 
which point substantial release of the MSN-encapsulated Dox (in red) was also 
observed (panels 1-3). The slower cellular uptake of CPD-MSN-Dox, when 
compared to that of CPD-Protein, was likely due to the much larger size of 
MSNs, but was nevertheless still faster than that of CPP-capped MSNs.149,150 
Over the course of the next 21 h, more Dox was released from CPD-MSN-Dox 
and entered cell nucleus (panels 6, 10 & 14 in Figure 4.20A), resulting in 
apoptosis in > 70% of cells (Figure 4.20B-C; 24-h treatment). Successful 
activation of endogenous caspase-3 activity and cleavage of PARP1 were 
observed as well. For cells treated with MSN-Dox (i.e no BiotinCPD capping; 12 
and 24 h incubation), intracellular fluorescence signals were detected in the red 
but not green channel, indicating cellular uptake of MSN-Dox was unsuccessful 
due to a lack of the surface-bound BiotinCPD (Figure 4.21), but leaked Dox from 
the nanoparticles was able to subsequently enter cells freely and cause cell 
death. Again, a small percentage of cell death detected in cells treated with 
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CPD-MSN (i.e. no Dox; Figure 4.20C) was attributed to the trace amount of 
iodoacetamide present in BiotinCPD.      
 
Figure 4.20. CPD-assisted MSN delivery.157 (A) Confocal images of HeLa 
cells treated with CPD-MSN-Dox (20 µg/mL) over 24 h at 37 oC. Dox (red), 
MSN (green) and Hoechst (blue) were colored accordingly. Arrowed: 
apoptotic cells. Scale bar = 20 µm. (B) In vitro enzymatic assay of the cell 
lysates (after 24-h cell treatment). RFU was recorded after 5 h incubation 
with Ac-DEVD-AMC (1 μM) with HeLa lysate (25 μg/reaction). (Inset) WB 
results showing the successful activation of endogenous caspase-3 and 
cleavage of PARP1 of treated cells. (C) Cell viability/apoptosis caused by 
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experiments were concurrently done with cells treated with MSNs alone, 
CPD-MSN or MSN-Dox.  
 
Figure 4.21. Confocal images of HeLa cells treated with MSN-Dox (20 
µg/mL) over 24 h at 37oC.157 (red, Dox, λex = 488 nm, λem = 580-650 nm; 
green, MSN, λex = 488 nm, λem = 500-560 nm; blue, Hoechst, λex = 405 nm, 
λem = 440-470 nm). (Inset) DIC images. Scale bar = 20 µm. 
 
4.8 Conclusion 
In this study, we have successfully designed and synthesized several 
novel cell-penetrating poly(disulfide)s. These CPDs (BiotinCPD, Ni-NTACPD & 
TzCPD), upon highly efficient bioorthogonal “conjugation”, either non-
covalently or covalently, to readily available cargos including recombinant 
proteins and suitably modified antibodies, were able to rapidly and efficiently 
deliver these cargos into different mammalian cells via endocytosis-
independent pathways. Rapid intracellular CPD depolymerization of the 
delivered cargos under highly reduced cytosolic environments subsequently 
released the proteins in their functionally active form, which may be further 
translocated to their intended subcellular organelles for additional biological 
processes. The successful intracellular delivery of antibodies by TzCPD 
indicates this method may be more broadly applicable in future for effective 
cellular delivery of many other therapeutic antibodies, which at present could 
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not be adequately achieved with other protein transduction methods.158 Unlike 
the siCPDs approach recently developed by Matile et al,152 who suggested thiol-
containing small molecule drugs and probes may be directly “grown” onto 
CPDs during polymerization, we have successfully developed CPD-capped 
MSNs for encapsulation of native small molecule drugs without the need of 
introducing thiol handles. With doxorubicin as an example, we found CPD-
MSN-Dox entered mammalian cells rapidly and was able to subsequently 
release free Dox into the cytosol. While more studies are needed to investigate 
the utilities of CPDs as novel “capping” agents for MSNs and other types of 
nanoparticles, our preliminary finding herein indicates that they may be more 
widely used in future for intracellular delivery of otherwise difficult-to-deliver 
drugs in a highly controllable manner.131-133,145-147 
One of the key features of our two-step, CPD-assisted approaches is 
their versatility and flexibility, enabling immediate delivery of a variety of 
cargos (recombinant proteins, antibodies and native small molecule drugs) with 
minimum chemical and genetic manipulations. The other feature is the rapid 
and “bioorthogonal” cargo-loading process – with different types of pre-
synthesized CPDs in hand, the resulting CPD-cargo conjugates could be 
prepared in a matter of minutes under aqueous conditions, and used immediately 
for subsequent cell delivery studies. The minimal cell cytotoxicity of these new 
CPDs and their cargo-loaded conjugates further highlights the unique advantage 
of this new cell-transduction method over other existing strategies, and ensures 
our entire delivery protocol is compatible with live cell experiments. Future 
work will focus on the expansion of the types of CPDs by using other 
conjugation chemistries, development of better CPD purification protocols, and 
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application of these CPDs for cell type-specific delivery of other therapeutically 
important drugs (including proteins, antibodies and small molecules).   





5.1 Profiling human Src homology 2 (SH2) domain proteins 
and ligand discovery using a peptide-hybrid small molecule 
microarray 
5.1.1 General Information 
All chemicals were purchased from company vendors and used without 
further purification. Fmoc-acid, HBTU, HOBt, TIS, PyBrOP and Rink Amide 
resin were purchased from GL Biochem (China). PL-FMP 4-Formyl-3-
methoxyphenoxy Resin (PL-FMP Resin, 0.9 mmol/g, 75~150 µm, Part 
no:1465-799) was purchased from Polymer Laboratories (USA). HPLC grade 
solvents were used for peptide synthesis. The reaction was carried out at room 
temperature and monitored by ninhydrin or chloranil test. HPLC and Mass 
spectra profiling were recorded on Shimadzu LC-ITTOP system using reverse-
phase Phenomenex Luna 2.6µm C18 100 Å 50 × 3.0 mm columns. Preparative 
HPLC was carried out on Gilson preparative HPLC system using Trilution 
software and reverse-phase Phenomenex Luna 5 μm C18(2) 100 Å 50 × 30.00 
mm column, to purify selected hits. 0.1% TFA/H2O and 0.1% TFA/CH3CN 
were used as eluents for both systems. The flow rates were 0.6 ml/min for HPLC 
and 8ml/min for preparative HPLC. SH2 domain were expressed, purified and 
labelled on beads. Gels were scanned on a Typhoon fluorescence gel scanner 
(GE Healthcare, USA). Plain glass slides were purchased from Sigma Aldrich 
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(USA) and the generation of avidin slides were performed as described 
previously.1 Microarray slides were scanned using a Tecan Launch LS 
Reloaded Microarray Scanner (TecanTrading AG, Switzerland) installed with 
suitable lasers: Cy3: λEx/Em= 532/575 nm; Cy5: λEx/Em= 633/692 nm. 
5.1.2 Expression and Labelling of Protein 
The mammalian SH2 domain collection was cloned into modified 
pET28 bacterial expression vectors with His tagged was obtained from Open 
Biosystems. All expression constructs were transformed into E.coli BL21 
(DE3) competent cells. The transformed cells were then plated onto the LB-
kanamycin agar plates and placed in the incubator at 37 °C for 16 hours. 
Overnight cultures were diluted 1:100 in LB media supplemented with 50μg/ml 
of kanamycin and grown at 37°C with shaking. When OD600 was about 0.6-
0.8, expression was induced with 0.1 mM of isopropyl β-D-1-
thiogalactopyranoside (IPTG) and cultures were grown further at 18 °C for 18 
h. After cell harvest (4 °C, 10000 g, 30 min), lysis buffer (pH 7.4, 50 mM Tris-
HCl, 300 mM NaCl) and 1mg/ml lysozyme were added. After incubation on ice 
for 20 min, lysis was performed by sonication (12× pulses of 10 s each at half 
maximal power, on ice), the cell debris was pelleted by centrifugation at 10000 
g, 20 min, 4 °C, which the supernatant was loaded into a column containing 50-
80 μl of Ni-NTA resin preequilibrated with wash buffer (pH 7.4, 50 mM Tris-
HCl, 300 mM NaCl, 20 mM imidazole). Following incubation for 2 h at 4 °C, 
the resin was washed 3 times with the wash buffer and the protein was finally 
eluted with elution buffer (pH 7.4, 50mM Tris-HCl, 300 mM NaCl, 200 mM 
imidazole). Fractions containing the desired proteins were pooled and dialysed 
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onto Microcon® centrifugal filter device (3kDa cutoff) and stored at -20 °C in 
PBS containing 20% glycerol. Protein concentration was determined from a 
standard curve using the Bradford protein assay (Bio-Rad) with BSA protein. 
Protein purity was determined by separation on a 15% SDS-PAGE gel by 
Coomassie® brilliant blue staining. 
5.1.2.1. Solution-phase Protein Labelling  
Protein samples were labelled with Cy5 dye (Amersham, G.E. 
Healthcare, USA) for 1 hour on ice, following manufacturer’s protocol.107 A 50 
µl protein sample at 1 mg/ml was quenched with 5 µl quench solution (3M 
hydroxylamine, 2.5M NaOH) for further 30min. The excess dye was removed 
with a Microcon® centrifugal filter device (3KDa cutoff). The labelled protein 
was determined by separation on a 15% SDS-PAGE gel by Coomassie® 
brilliant blue staining. 
5.1.2.2. Protein Labelling while on Solid-support  
Following washing the Ni-NTA resin with wash buffer, the resin was 
washed twice with PBS. To the resulting protein-bound resin, a 200 µl Cy5-
NHS ester solution(Amersham, G.E. Healthcare, USA) was added to label the 
protein. Following incubation on ice for 1 hour, the unreacted dye was quenched 
with 20µl quench solution for a further 30 min. 15ml PBS was used to wash the 
labelled-resin thrice to remove the excess dye. The protein was finally eluted 
with elution buffer (pH 7.4, 50 mM Tris-HCl, 300 mM NaCl, 200 mM 
imidazole). Fractions containing the desired protein were pooled and dialysed 
onto Microcon® centrifugal filter device (for 3 KDa) and stored at -20 °C with 
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PBS containing 20% glycerol. The labelled protein was determined by 
separation on a 15% SDS-PAGE gel by fluorescence scan on Typhoon. 
5.1.3. Synthesis of Peptide-small molecule Hybrid Library  
  
Scheme 5.1. Synthesis of the peptide-small molecule library102 
The library was synthesized using the standard Fmoc strategy combined 
with IRORITM technology (Scheme 5.1). Briefly, the 396-member library was 
synthesized on PL-FMP resin 50 mg resin was used for each compound. The 
resin was first swelled in DCE for 2 h and then coupled the amine building 
blocks (X1-44) onto the PL-FMP resin by reductive animation. Four molar 
equivalents of the amine building block was added in DCE and the incubated 
with shaking for 2 h. Next, HOAc(1%) and Na(OAc)3 (6.0 eq.) in DCE was 
added and the reaction was further shaken for 16 h. Subsequently, the resin was 
washed thoroughly with THF, MeOH and DCM and dried in high vacuo. To 
confirm completion, the reaction was monitored using chlorinal test. Next, the 
resin was coupling with Fmoc-Tyr[PO(OBzl)OH]-OH(4.0 eq.), PyBrOP(4.0 
eq.) and DIEA(8.0 eq.) in DMF. After reacting for overnight at room 
temperature, the result resin was extensive washed with DMF and DCM and 
dried. To confirm completion, the reaction was also monitored by chlorinal test. 
Subsequently, the Fmoc group was removed by 20% piperidine and ready for 
next step. Repeat the cycle using HOBt/HBTU/DIEA coupling method until the 
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Biotin-GG linker was coupled. Cleavage was performed with TFA/H2O/TIS 
(95:2.5:2.5, total 2 ml) for each micro-reactor. After continuous shaking for 6 h 
at room temperature, the resin was separated and the filtrate was collected and 
concentrated under reduced pressure. Cold ether (chilled to -20 °C, ~5 ml) was 
added to the liquid concentrates to precipitate the peptide-small molecule 
compounds. The mixture was stored at -20 °C overnight. Upon centrifugation, 
the ether layer was decanted off and washed with ether twice. The precipitates 
were then dried thoroughly in vacuo, dissolved in DMSO (0.5 ml) and stored at 
-20 °C for future use. The 14 individual hits were also re-synthesised using the 
procedure above. Each micro-reactor reactor contained 200 mg of PL-FMP 
resin. Unique RF tags were used to facilitate sorting. The peptide-small 
molecule compounds were further purified using preparative HPLC (Gilson) 
and lyophilised. LC-MS was performed to ensure the peptide-small molecules 
were of correct mass and pure for subsequent microarray experiments, the 
spectrums and MS results are shown in Figure 5.1 
5.1.4. Pro-Q Staining and Detection 
The spotted slide was washed with distilled water and stained with Pro-
Q™ Diamond dye for 1 h at room temperature in a humidified chamber. The 
slide was then de-stained with a solution of 20% acetonitrile in sodium acetate 
(pH 4) for 25 min, rinsed with water, dried and scanned under the Cy3 channel 
(λex/em: 532/575 nm). 
5.1.5. Microarray Preparation  
The peptide-small molecular hybrid library stock solutions were 
prepared to approximately 1.0 mM in 50% DMSO and 50% PBS and were 
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distributed in Genetix384 well plates. Stock spotting plates were not recycled 
more than 5 times, to minimize variability. Avidin coated glass slides (75x25 
mm) were spotted on an OmniGrid® Accent (DigiLab, USA) microarray spotter 
with the print head installed with four Stealth SMP8B Micro-spotting pins 
(TeleChem USA). Spots generated were approximately 295 μm diameter and 
were printed with a spot-spot spacing of 450 μm. The pins were rinsed in 
between samples using two cycles of wash (for 5 s) and sonication (for 5 s) in 
reservoirs containing 70% ethanol followed by drying under reduced pressure 
(for 5 s). The slides were allowed to stand for overnight on the printer platform 
and stored at 4 °C until use (spotted slides were stable for 6 months under these 
storage conditions). Before incubation with the labelled protein, the slides were 
rinsed with PBS (pH 7.4) for 20 min and blocked with PBS containing 1% BSA 
for 1 h. For studies with the 396-member library, all were spotted on the slide 
in duplicate. For the KD experiments, a new microarray was fabrication where 
up to 8 identical subarrays were created on the same slide using the same set of 
14 selected hits. ProQ assays were performed to ensure batch-batch variability. 
5.1.6 Data extraction and analysis  
Microarray data was extracted using the Array-Pro® software. Values 
from duplicated points and was background subtracted and averaged 
(Duplicated spots with a standard deviation >0.8 were rejected) and were 
depicted in grey in heatmaps, to indicate data not obtained. 
5.1.7. KD Analysis of Selected High Binders  
14 hits including the previous synthesized hits and the newly 
synthesized were spotted onto the same slide were up 8 identical subarray were 
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generated on the same platform, allowing consistent/uniform screening and 
binding of Lck SH2 domain. By using dose-dependent experiments, as previous 
described,101 we extracted the binding data of Lck SH2 domain. The 
corresponding KD was generated by fitting the data to the following equation, 
under the assumption that equilibrium was achieved during the incubation 
period:  
Observed fluorescence of x=
(𝑀𝑎𝑥𝑖𝑢𝑚 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒,𝑋) × [𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛]
𝐾𝐷+ [𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛]
 
Saturation dynamics observed when plotting Observed Fluorescence 
against the applied Protein Concentration were fitted the above equation using 
the Graph pad Prism software ver 4.03 (GraphPad, San Diego, USA) revealing 
the binding dissociation constant, KD.
101 
5.1.8. Thermfluor Based Melting Point Shift Assay  
Thermal shift assay was determined by the Thermal Shift Assay Dye kit 
(Applied Biosystem, #4461146) followed by the manufacturer’s guidelines. The 
Lck and Grb2 SH2 domain protein was added to a final concentration of 40µM 
in buffer. (5 µl Protein Thermal ShiftTM buffer, 2.5 µl Protein Thermal 
ShiftTM dye). The final volume was 20 µl/well in RT-PCR 96-well white 
microplates. The temperature gradient was performed in the range of 30-80 oC, 
using a 7500 real-time PCR instrument from Applied Biosystems (Carlsbad, 
CA) with a standard ramp of 1% over the course of 60 min. The compound 
screening was performed at the 400 µM (in 4% DMSO) concentration. The 
detection of protein unfolding was performed with an excitation wavelength of 
567 nm and an emission of 591 nm. The Prism software ver 4.03 (GraphPad, 
San Diego, USA) was used to analysed the result.178 
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5.1.9. HPLC Result 
All compounds were purified and characterized by LCMS and were 
shown to be of correct molecular weight and sufficient purity to be used. Below 
are the LCMS profiles of the 14 potential hits. 
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Figure 5.1. LC-MS profiling of resynthesized 14 hits102 
5.2. Accelerated cellular on- and off-target screening of 
bioactive compounds using microarrays 
5.2.1. General Information 
All probes were synthesized as reported.117,119 Other chemicals were 
purchased from vendors and used without further purification, unless indicated 
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otherwise. HBTU, HOBT, EDC were purchased from GL Biochem (China). 
Tyramide signal amplification kits were purchased from Invitrogen (USA). Gels 
were scanned on a Typhoon fluorescence gel scanner (GE Healthcare, USA). 
Microarray slides were scanned using a Tecan Launch LS Reloaded Microarray 
Scanner (Tecan Trading AG, Switzerland) installed with suitable lasers: Cy3: 
λEx/Em= 532/575 nm; Cy5: λEx/Em= 633/692 nm.  
5.2.2. Expression and Labelling of Protein 
Proteins were purified from bacterial cell lysates, as described.179 The 
pre-cultures of LB with single colony containing c-Src (32 kDa) were grown at 
37 oC to reach OD600 0.6~0.8. The expression was then induced by 0.1mM IPTG 
and cultures were further grown at 18oC for 18h. The harvested pellets were 
resuspended with lysis buffer and incubated for 20min. After sonication, the 
insoluble cell debris was removed by centrifugation. The resulting supernatant 
was incubated with Ni-NTA beads for 2 h at 4 oC. After washing with wash 
buffer, target proteins were eluted in elution buffer. The desired proteins were 
dialysed with Microcon® centrifuge filter device and stored at -20oC in Hepes 
containing 20% glycerol. 
5.2.3. Structure of the Tri-functional Linker and Probes 
 
Figure 5.2. Structure of Biotin-TER-N3
180 
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Table 5.1. Design and structures of ABP and AfBP 
 
5.2.4. Pure Protein Labelling Experiment 
1 mg/ml pure protein (c-Src) was incubated with 10 µM probes for 2 h 
at room temperature following UV irradiation for 20 min for AfBPs. The 
resulting proteins were tagged with TER-Biotin-N3 via click chemistry. After 2 
h of click reaction, labelled proteins were washed with acetone (1×) and 
methanol (2×) to remove excess dye. After washing, 2% SDS in TBS was added 
to dissolve proteins; final concentration was around 1mg/ml. In gel fluorescent 
scanning was used to visualize the labelled protein bands. Both in-gel 
florescence scanning (FL) and Coomassie staining (CBB) were always carried 
out on the gels, following separation of labelled samples by SDS-PAGE.  
5.2.5. Spike-In and In-situ Proteome Labelling  
The procedure is similar to our previous reported methods but with 
further modification as described.119 For spike in labelling, probes were added 
to a final concentration of 10 µM into 1mg/ml of fresh cell lysate with or without 
spiked proteins and incubated for 2 h at room temperature. For activity-based 
probes, 20 min UV irradiation was required. The resulting lysate was tagged 
with TER-Biotin-N3 via click chemistry. The reactions were further incubated 
for 2 h at room temperature with gentle mixing before the reaction was 
terminated by addition of acetone. Precipitated proteins were subsequently 
washed with methanol twice to remove the excess dye following dissolved in 
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TBS with 2% SDS. Around 20 µg proteins were separated by SDS-PAGE gel 
and then visualized by in-gel fluorescence scanning. For in situ labelling, cells 
were grown between 80% to 90% confluence. The growth medium was 
removed and the cells were washed with PBS twice. Then cells were treated 
with DMEM containing 10 µM probes. After 5 h incubation at 37oC/5% CO2, 
the medium was aspirated and cells with activity-based probes were irradiated 
by UV for 20 min on ice. The cells were trypsinized and spun down. The 
resulting cell pellets were resuspended in lysis buffer and homogenized by 
sonication, and brought with final concentration of 4-8mg/ml in Hepes buffer. 
All subsequent procedures were performed in the same was as described for the 
in vitro labelling experiments.  
5.2.6. Array-based Target Identification and Validation 
Avidin slides were prepared as previously reported.4 Slides were 
blocked with 1% BSA for 1 h at room temperature before sample spotted to 
reduce non-specific binding as much as possible. The labelled proteins were 
dissolved in Spotting Buffer (20% DMSO in TBS) in 1:1 ratio and spotted onto 
avidin slides. Spike-in and in situ labelling samples were spotted onto slides 
with a final concentration of 2 or 4 mg/ml. After incubation for 2 h, avidin slides 
were washed with 0.5% TBST for 6 times, 5 min per time. Slides with three 
sub-grids were first incubated with different antibodies separately for 1.5 h at 
room temperature. After washing with TBST, avidin slides were incubated with 
secondary antibody for 1 h at room temperature following washed with TBST. 
Targets were identified by Cy5 tyramide signal amplification kits according to 
manufacturer's protocol with slight modifications. Generally, tyramide was 
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diluted into 1:400 with amplification buffer containing 0.015% H2O2. A 200µl 
reagent was applied onto each slide under cover slip with 15 min exposure time 
at room temperature. After development, the resulting slides were washed with 
TBST for 5 times and scanned by Tecan Launch LS Reloaded Microarray 
Scanner in the Cy5 channel. Slides were generally scanned under a PMT setting 
of 140.  
 
Table 5.2. Antibodies used for screening and their correspoding dilution 
 
5.2.7. Data Extraction and Analysis 
Microarray data was extracted using the Array-Pro®software. Values 
from duplicated points were background subtracted and averaged. For each 
antibody, signals were first normalized by its mean and subtracted by DMSO 
treated controls. The coloured array heatmaps were produced using Cluster 3.0 
and Java Treeview 3.0 (http://sourceforge.net/projects/jtreeview/files).  
5.2.8. Pull-down Experiment 
To identify potential cellular targets and off-targets of the probes and 
their parental compounds, pull-down (PD) experiments were carried out, 
followed by Western blotting (WB). The general pull-down procedure was 
Antibody Company WB Microarray Product code
anti-c-Src Santa Cruz 1：500 1：100 sc-8056
anti-PDI Santa Cruz 1：500 1：50 sc-166474
anti-PKA Santa Cruz 1：2000 1：500 sc-903
anti-MEK1 Abcam 1：2000 1：100 ab32091
anti-CDK1 Abcam 1：10000 1：1000 ab133327
anti-Tubulin Abcam 1：5000 1：500 ab6064
anti-rabbit Cell signalling 1：5000 1：500 7074S
anti-mouse Santa Cruz 1：5000 1：500 sc-358917
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based on previously reported procedures.161,187 In situ labelling was carried out 
as described above. After labelling, the reaction was reacted by click chemistry 
with TER-biotin-N3 before acetone precipitated, methanol washed and 
resolubilized in 2% SDS in TBS with brief sonication. This resuspended sample 
was then incubated with avidin-agarose beads (100 µL/mg protein) for 3 h at 
room temperature. After centrifugation, supernatant were removed. The beads 
were washed with 0.5% SDS once and 0.1% SDS PBS for four times. After 
washing, the beads were boiled in 1× SDS loading buffer (200 mM Tris pH 6.8, 
400 mM DTT, 8% SDS) for 15 min. Control PD using DMSO was carried out 
concurrently. WB experiments were carried out as previously described using 
the corresponding antibodies.  
5.2.9. Recombinant PKA Labelling 
1 µg/ml pure protein (PKA) was incubated with probes (P1 and PU-1) 
of varying concentrations (0.1, 0.2, 0.5, 1, 2, 5 µM) for 2 h at room temperature 
before UV irradiation for 20 min for AfBPs. The resulting proteins were tagged 
with TER-Biotin-N3 via click chemistry for 2 h. SDS-PAGE gel profiling were 
carried out for the sample without further purification before silver stain.  
5.3. Intracellular Delivery of Functional Proteins and Native 
Drugs by Cell-Penetrating Poly(disulfide)s 
5.3.1. General Information. 
All chemicals were purchased from commercial vendors and used 
without further purification. All 1H NMR and 13C NMR spectra were carried 
out on a Bruker ACF-300 or 500 MHz NMR spectrometer. Chemical shifts were 
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reported in parts per million relative to internal standard tetramethylsilane 
(Si(CH3)4 = 0.00 ppm) or residual solvent peaks (DMSO-d6 = 2.50 ppm, DMF-
d7 = 8.03, 2.92, 2.75 ppm, CDCl3 = 7.26 ppm, D2O = 4.79 ppm). 
1H NMR data 
was reported as follows: chemical shift in ppm from the respective internal 
standard, multiplicity (s = singlet, br = broad, d = doublet, t = triplet, m = 
multiplet, dd = doublet of doublets, ddd = doublet of doublets of doublets, dt = 
doublet of triplets or overlap of nonequivalent resonances, dq = doublet of 
quartets), integration, coupling constant. Mass spectra were recorded on a 
Finnigan LCQ mass spectrometer, a Shimadzu LC-IT-TOF spectrometer or a 
Shimadzu LC-ESI spectrometer. Analytical HPLC system was equipped with 
an autosampler, using reverse-phase Phenomenex Luna 5 μm C18 100 Å 50 × 
3.0 mm columns. 0.1% TFA/H2O and 0.1% TFA/acetonitrile were used as 
eluents for all HPLC experiments. Analytical GPC was carried out on a Waters 
Alliance e2965 model with an Waters™ Ultra-hydrogel Linear Column (10 µm, 
7.8 mm × 300 mm, 500-10 M) equipped with a guard column (200 Å, 6 µm, 6 
mm × 40 mm) and a Waters™ RI 2414 detector. Pure deionized water was used 
as the mobile phase at the flow rate of 0.8 mL/min. In-gel fluorescent scanning 
was carried out with a Typhoon 9410 fluorescence gel scanner (GE Amersham). 
High-content screening (HCS) were acquired with an In-Cell Analyzer 2200 
(GE Healthcare Life Science) equipped with a solid-state, multi-wavelength 
illuminator (λex = 390 ± 18 nm; λex = 438 ± 24 nm; λex = 475 ± 28 nm; λex = 513 
± 17 nm; λex = 542 ± 27 nm; λex = 575 ± 25 nm; λex = 632 ± 22 nm). Images were 
processed and quantified with In-Cell Developer Toolbox software 1.9.2. 
Confocal images were acquired on a Leica TCS SP5X Confocal Microscope 
System equipped with Leica HCX PL APO 40×/0.85 Dry CORR CS, 405 nm 
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diode laser, argon ion laser, white laser (470 nm to 670 nm, with 1 nm 
increments, with 8 channels AOTF for simultaneous control of 8 laser lines, 
each excitation wavelength provides 1.5 mV), a PMT detector ranging from 420 
nm to 700 nm for steady state fluorescence. Images were processed with Leica 
Application Suite Advanced Fluorescence (LAS AF). Antibodies were 
purchased from the following vendors: anti-PARP1 (#9532, Cell Signaling 
Technology) Rabbit, anti-cleaved caspase-3 (#9661, Cell signaling Technology) 
Rabbit, anti-His (34460, QIAGEN) HRP, anti-β-tubulin, (#ab6064, abcam) 
Rabblit, HRP-conjugated anti-Rabbit IgG (#7074, Cell signaling Technology), 
Alexa Fluor® 488 Goat Anti-Rabbit IgG (#A11008, Invitrogen). Western 
blotting was done by using the ECL Plus Western Kit (GE Healthcare). TCO-
PEG3-Maleimide and ThioLinker-TCO
TM were purchase from 
http://www.clickchemistrytools.com/. Endosome inhibitors 5,5’-dithiobis-2-
nitrobenzoic acid (DTNB), chlorpromazine (CPZ), wortmannin (w), and 
methyl-β-cyclodextrin (mβCD) were purchased from Sigma-Aldrich. 
Fluorescence-activated cell sorting (FACS) experiments were carried out on a 
BD Accuri™ C6 cell analyzer (Beckman Coulter). Recombinant (His)6-tagged 
caspase-3 and BRD-4 were expressed, purified as previous described.1 The 
Tetrazine-containing dye reporter, TER-Tz2 (in Figure S1D) was prepared as 
previously described.2 Tetraethylorthosilicate (TEOS), 3-
(trihydroxysilyl)propyl methylphosphonate monosodium (TPMP), N-
cetyltrimethylammonium bromide (CTAB) were purchased from Sigma. 
Doxorubicin hydrochloride (Dox) was obtained from Selector Ltd. All other 
reagents were analytical grade and used without purification. All aqueous 
solutions were prepared using diethylpyrocarbonate (DEPC)-treated ultrapure 
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water from a Milli-Q system. Transmission electron micrographs (TEM) were 
carried out on a JEOL JEM 200CX transmission electron microscope with an 
accelerating voltage of 200 kV. The ordered structures of the MSN materials 
were confirmed by small angle powder XRD on a Thermo ARLTM SCINTAG 
X’TRA diffractometer using Cu-Kα radiation. The specific surface areas were 
calculated from the adsorption data in the low pressure range using the BET 
model and pore size was determined using the Barrett-Joyner-Halenda (BJH) 
method. UV-Vis absorption and ﬂuorescence spectra were measured by using 
Shimadzu UV-Vis spectrometer. The particle size and distribution was 
determined by dynamic light scattering (DLS) on a Malvern Nano-ZS90 particle 
size analyzer.  
5.3.2. Chemistry. 
All CPD building blocks were synthesized by using procedures 
modified from published protocols,151,188-191as described in detail below.  




Scheme 5.2. Initiators synthesis.157 (a) EDC.HCl, cystamine 
dihydrochloride, trimethylamine, DMF, 18 h, r.t., 91%; (b) TCEP, 50% 
DMF/H2O, 30 min, r.t.; (c) EDC.HCl, cystamine dihydrochloride, 
trimethylamine, DMF, overnight, r.t., 91%; (d) TCEP, 50% DMF/H2O, 30 
min, r.t. ; (e) Bromoacetic acid, 2 M aqueous NaOH, 2 h, r.t., then 19 h, 50 
°C, 80%; (f) H2, Pd/C, MeOH, 12 h, r.t., 75%; (g) 4-butyrothiolactone, 
NaHCO3, 72 °C, 15 h, 70%; (h) CDI, ethylene diamine, DCM, 2 h, r.t., 78%; 
(i) 1H-pyrazole-1-carboxamidine hydrochloride, DCM, 4 h, r.t., 56%. r.t. = 
room temperature 
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Biotin disulfide (1). Biotin disulfide was synthesized and characterized 
by following a reported procedure.188 1H NMR (300 MHz, DMF-d7) δ 8.10-7.96 
(m, 2H), 6.34 (dd, J = 23.5, 6.8 Hz, 4H), 4.47 (dd, J = 7.7, 5.1 Hz, 2H), 4.32-
4.28 (m, 2H), 3.47 (dd, J = 12.8, 6.5 Hz, 4H), 3.31-3.11 (m, 2H), 2.93-2.91 (m, 
4H), 2.74 (s, 4H), 2.32 (dt, J = 29.1, 7.3 Hz, 4H), 1.80-1.42 (m, 12H). 
Initiator Biotin-SH (I1; 2). 50 mM compound 2 in 50% DMF/water 
was acquired by 30 min vigorous agitation at room temperature of an equal 
volume mixture of 1 M TCEP (in H2O) and 50 mM biotin disulfide (in DMF), 
and immediately used, without further purification, for subsequent polymer 
synthesis. 
Tetrazine disulfide (3). A solution of 4-(6-methyl-1,2,4,5-tetrazin-3-
yl)benzoic acid (100 mg, 0.46 mmol), EDC·HCl (106.4 mg, 0.56 mmol), 
cystamine dihydrochloride (57 mg, 0.25 mmol) and triethylamine (211 µL, 1.52 
mmol) in DMF (5 mL) was kept at room temperature for 18 h, then concentrated 
in vacuo. The resulting residue was triturated with H2O, providing the pure 
tetrazine disulfide as a pink solid (115 mg, 91%). 1H NMR (500 MHz, DMSO-
d6) δ 8.90 (t, J = 5.5 Hz, 2H), 8.53 (d, J = 8.5 Hz, 4H), 8.09 (d, J = 8.6 Hz, 4H), 
3.62 (dd, J = 12.8, 6.4 Hz, 4H), 3.12-2.90 (m, 10H). 13C NMR (75 MHz, DMSO-
d6) δ 167.28 (s), 165.57 (s), 162.83 (s), 137.49 (s), 134.24 (s), 128.17 (s), 127.33 
(s), 37.09 (s), 20.86 (s). One carbon peak was merged with solvent pick. MS 
(ESI): m/z [M+Na]+ calcd 571.1417, found 571.1413.  
Initiator Tz-SH (I3; 4). 50 mM compound 4 in 50% DMF/H2O was 
acquired by 30 min vigorous agitation at room temperature of an equal volume 
mixture of 1 M TCEP (in H2O) and 50 mM tetrazine disulfide (in DMF), and 
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immediately used, without further purification, for subsequent polymer 
synthesis. 
N-(5-Carbobenzyloxyamino-1-carboxypentyl) iminodiacetic acid 
(5).Compound 5 was synthesized and characterized according to a published 
protocol.4 1H NMR (300 MHz, DMSO-d6): δ 7.42-7.13 (m, 5H), 5.00 (s, 2H), 
3.61-3.39 (m, 4H), 3.35 (t, 1H, J = 7.2 Hz), 2.96 (d, 2H, J = 5.9 Hz), 1.79-1.01 
(m, 6H). 
N-(5-Amino-1-carboxypentyl) iminodiacetic acid (6). Compound 6 was 
synthesized and characterized according to a published protocol.4 1H NMR (500 
MHz, D2O): δ 3.93 (s, 5H), 3.01 (t, 2H, J = 7.2 Hz), 1.96-1.56 (m, 6H). 
Initiator NTA-SH (I2; 7). Compound 7 was synthesized and 
characterized according to a published protocol.5 1H NMR (300 MHz, D2O): δ 
3.86 (s, 5H), 3.22 (s, 2H), 2.75 (t, 2H), 2.38 (t, 2H, J = 7.1 Hz), 2.03-1.59 (m, 
8H). 
N-(2-aminoethyl)-5-(1,2-dithiolan-3-yl) pentanamide (8). Compound 
8 was synthesized and characterized according to a published procedure.6 1H 
NMR (500 MHz, CDCl3): δ 5.94 (sbr, 1H), 3.59-3.56 (m, 1H), 3.30 (dt, J = 11.4 
Hz, 2H), 3.21-3.08 (m, 2H), 2.88-2.79 (m, 2H), 2.55-2.31 (m, 1H), 2.22 (t, 2H, 
J = 7.4 Hz), 1.91-1.84 (m, 1H), 1.76-1.40 (m, 8H). 
Monomer M (9). Compound 9 was synthesized and characterized based 
on a published procedure.151,191 1HNMR (500 MHz, MeOD): δ 8.44 (d, 1H, J = 
3.0 Hz), 7.94 (d, 1H, J = 1.5 Hz), 7.57 (d, 1H, J = 1.7 Hz), 6.71 (dd, 1H, J = 3.0, 
1.6 Hz), 6.29 (t, 1H, J = 2.1 Hz,), 3.99 (s, 1H), 3.67-3.40 (m, 1H), 3.30-3.22 (m, 
4H), 3.20-2.98 (m, 2H), 2.54-2.33 (m, 1H), 2.21 (t, J = 7.4 Hz, 2H), 1.94-1.76 
(m, 1H), 1.77-1.32 (m, 6H). 
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General procedure for polymer synthesis and characterizations. The 
CPD polymers were synthesized and characterized according to published 
procedures,151,191 and modified where applicable. Briefly, stock solutions of the 
monomer (M; 2 M in DMF), initiator precursor-disulfide (50 mM in DMF), 
terminator (T; iodoacetamide, 0.5 M in H2O, fresh), TCEP (1 M in H2O) and 
TEOA buffer (1 M, pH = 7.0) were prepared. The initiator (I1/I2/I3) was first 
generated in situ, by mixing 5 μL of the initiator precursor stock solution with 
5 μL of the TCEP solution (NTA-SH was treated with TCEP as well, to ensure 
any possible disulfide formation) followed by vigorous shaking for 30 min at 
room temperature. Subsequently, 80 μL of TEOA buffer (for Biotin-SH and 
NTA-SH initiated polymerization) or DMF/TEOA 50% mixture (for Tz-SH 
initiated polymerization) and 10 μL of the monomer stock solution were added 
to the reaction mixture. After 30 min of agitation at room temperature, the 
polymerization reaction was quenched by addition of 1.9 mL of the terminator 
stock solution. The resulting polymer was purified with a NAPTM-5 desalting 
column (GE Healthcare) against H2O in the same day, by following protocols 
provided by the vendor. The elution was lyophilized and kept in -20 oC. The 
molecular weight of each polymer was determined by analytical GPC under 
conditions as described in the General Information, with standard molecular 
weight markers used for calibration. Quantification of TzCPD was achieved by 
UV-Vis measurements of the tetrazine absorbance at the wavelength of 520 nm, 
and the tetrazine disulfide (3) of different concentrations (50, 100, 200, 400 and 
500 µM) was used to generate the corresponding calibration curve (Figure S3C). 
The polymer concentration of the obtained stock solution was estimated to be 
~200 μM. The concentrations of other CPDs were assumed to be the same. We 
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tried to make the free thiol of various initiators, but found they were oxidized 
rapidly, and therefore were of limited practical use. Therefore we developed the 
TCEP-reducing protocols to make the thiols in situ and use them immediately. 
We took pain in optimizing the amount of TCEP (ensuring min TCEP needed 
was used). We initially tried 1-fold and 3-fold TCEP to reduce tetrazine 
disulphide. But it takes more than half an hour to complete the reduction process. 
Therefore, 10-fold of TCEP was used to make sure the complete and fast 
reduction of initiator. We found that this amount of excess TCEP did not affect 
the subsequent polymerization reaction, as during polymerization, the 
concentration of TCEP was significantly diluted. Furthermore, during 
polymerization, the amount of monomer used was much higher than that of 
TCEP (4 folds). Finally, as soon as the polymerization reaction was completed, 
the newly formed polymer was immediately purified by dialysis which would 
remove all remaining TCEP. 
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5.3.3. Protein Bioconjugation by CPD. 
  
Figure 5.3. Labeling process of avidin, BRD-4, BSA and AbFC.157 (A) 
Recombinant avidin was labeled with Cy5-NHS to generate AvidinCy5. (B) 
Recombinant (His)6-tagged BRD-4 was labeled with Cy5-NHS to generate 
BRD-4Cy5. (C) Recombinant BSA was first labeled with TCO via site-
specific conjugation between TCO-PEG3-Maleimide and the single free 
cysteine present in the protein. Next, TCO-BSA was fluorescently labeled 
with Cy5-NHS to obtain TCO-BSACy5. (D) For antibody conjugation, a 
commercially available FC-labeled antibody (i.e. AbFC) was used, and the 
TCO moiety was site-specifically introduced to the antibody by first 
reducing the disulfide bond linkage in the antibody, followed by treatment 









Figure 5.4. Formation of CPD-Protein and CPD-MSN-Dox.157 (A) The 
formation of CPD-BSA between TzCPD and TCO-BSACy5, and CPD-Ab 
between TzCPD and TCO-AbFC, via TCO-tetrazine bioorthogonal ligation. 
(B) Non-covalent formation of CPD-Avidin between BiotinCPD and 
AvidinCy5, CPD-BRD-4 between Ni-NTACPD and BRD-4Cy5, and CPD-
Casp-3 between Ni-NTACPD and (His)6-tagged caspase-3, via affinity 
interaction. (C) “Capping” of small molecule drug-loaded MSNs with CPD 
via electrostatic charge-charge interaction between the negatively charged 
MSN-Dox and positively charged CPD (in this case, BiotinCPD was used). 
 
20 μL of NaHCO3 (500 mM in H2O) and 10 μL of Cy5-NHS (GE 
Healthcare Life Science in DMSO) were added to an avidin solution (10 mg/mL, 
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with a MicroSpin G25 Column (GE Healthcare Life Sciences) by following the 
vendor’s protocol (Figure 5.3A). The dye-to-protein ratio in the labeling 
reaction of AvidinCy5 was determined to be 0.68 by UV/fluorescence 
measurement (at 650 nm) by using a Nanodrop™ fluorescence spectrometer 
(Thermo Scientific). Similarly, 20 μL of NaHCO3 (500 mM in H2O) and 10 μL 
of Cy5-NHS (GE Healthcare Life Science in DMSO) were added to a (His)6-
tagged BRD-4 solution (10 mg/mL, 100 µL in PBS).32,192 After 30 min 
incubation on ice, the excess dye was removed by MicroSpin G25 Column 
(Figure 5.3B). The dye to protein ratio of BRD-4Cy5 was determined to be 0.52 
as determined by UV/fluorescence measurement (at 650 nm). For labeling of 
BSA, 1 mg of the protein dissolved in 100 μL of PBS (pH = 7.4) was reacted 
with 2.5 μL of TCO-PGE3-Maleimide (stock: 2 mM in DMSO) for 4 h at room 
temperature. Subsequently, excessive TCO-PGE3-Maleimide was removed by 
G25 Column. To the resulting protein fraction, 20 μL of NaHCO3 (500 mM) 
and 10 μL of Cy5-NHS were next added. After incubation on ice for 30 min, 
the excessive dye was removed by G25 column (Figure 5.3C). The dye to 
protein ratio of TCO-BSACy5 was determined to be 0.86 determined as earlier 
described.  
The labeling of the commercially available, fluorescently labeled 
antibody was carried out by following published protocols.159 Briefly, 1 mg/mL 
of the AbFC (8 nM) in PBS buffer (100 mM sodium phosphate, 150 mM sodium 
chloride, 10 mM EDTA, pH = 7.5) was treated with 10 mM TCEP (stock: 500 
mM in H2O) for 30 min at room temperature, to reduce the disulfide bond. The 
excessive TCEP was subsequently removed by G25 column as earlier described. 
The resulting desalted AbFC was subsequently incubated with 40 nM of the 
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ThioLinker-TCOTM (from stock solution; 4 mM in DMSO) for 6 h. At the end, 
the excessive ThioLinker-TCOTM reagent was removed by G25 spin column. 
The labeling efficiency of TCO-AbFC was determined by in-gel fluorescence 
scanning of the labeled protein upon conjugation with a Tetrazine-containing 
dye reporter (TER-Tz2 in Figure 5.3D), as previously described.187 As protocols 
reported, the ratio of ThioLinker-TCOTM to on AbFC is 4 to 1. Once conjugated 
with TER-Tz2, there was a shift around 10 KDa of TCO-AbFC in SDS-PAGE 
gel.  
As shown in Figure 5.4, for CPD-BSA, 5 µM of TzCPD was mixed with 
5 µM of TCO-BSACy5 in PBS buffer, resulting in instantaneous and quantitative 
formation of the desired product, which was then used directly without further 
purifications. For CPD-Avidin, 20 µM of BiotinCPD was incubated with 5 µM 
of AvidinCy5 for 10 min at room temperature in PBS to obtain the desired 
product. For the generation of Ni-NTACPD, 15-fold excess of NiCl2 was added to 
NTACPD in 10 mM HEPES (pH = 7.0), and the resulting mixture was incubated 
overnight at 4 oC.193 Free nickel ion was removed by dialysis with a slide-A-
lyzer™ (3.5K Mw cutoff; Thermo Scientific) against 10 mM HEPES (pH = 7.9) 
for three times. Subsequently, 15 µM of the resulting Ni-NTACPD was incubated 
with 5 µM BRD-4Cy5 to give CPD-BRD-4. The preparation of successful CPD 
conjugates and CPD depolymerization on selected protein samples were 
analyzed by SDS-PAGE gel and in-gel fluorescence scanning (Figure S3B). 
Briefly, 10 nM of CPD-Avidin was treated with GSH (10 mM) or HeLa lysate 
(1 mg/mL, freshly prepared in PBS) for 1 h at 37 oC.153 Subsequently, DTT-free 
loading dye was added to the mixture, and without boiling (to prevent 
dissociation of avidin/biotin complex), the samples were directly analyzed by 
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15% SDS-PAGE gel (DTT-free) followed by in-gel fluorescence scanning. 
AvidinCy5 (CPD-free) was carried out concurrently as negative control. For 
preparation of CPD-Casp-3, CPD-Ab and CPD-MSN-Dox.  
5.3.4. Biochemical and Cellular Experiments 
5.3.4.1 Confocal Laser Scanning Microscope (CLSM) 
HeLa cells were seeded at 4-well glass-bottom dish (Greiner Bio-One) 
and grown until 50~60% confluency. Upon medium removal, cells were treated 
with 250 μL of 50 nM CPD-Protein (from 5 µM stock, freshly prepared in PBS) 
in DMEM medium. HeLa cells incubated with proteinCy5 (CPD-free) were 
done concurrently as negative controls. The cells were incubated for 1 h at 37 
oC before washing with PBS (containing 0.1 mg/mL heparin) for three times. 
For protein transfection experiment, an equal amount of proteinCy5 (12.5 pmol) 
was transfected by using the commercially available Pro-JectTM Protein 
Transfection reagent (Thermo Scientific) at the recommended volume by 
following the vendor’s protocols. Briefly, 12.5 pmol of proteinCy5 in 25 µL PBS 
was mixed with 2.5 µL of the Pro-JectTM reagent for 5 min at room temperature. 
The complex was then added to an imaging-compatible petri dish, followed by 
incubation further for 1 h in serum-free DMEM medium, and washing with PBS 
(containing 0.1 mg/mL heparin). Where applicable, HeLa cells were further co-
stained with CellMaskTM Orange (180 nM) and Hoechst (for an additional 15 
min) prior to the completion of the above protein delivery protocol. 
Subsequently, DMEM medium was re-introduced into the cells, which were 
then imaged in a Leica TCS SP5X Confocal Microscope System at different 
detection channels (CPD-BSA channel: λex = 643 nm, λem = 665-740 nm; 
- 118 - 
 
 
CellMask™ membrane tracker channel: λex = 543 nm, λem = 555-650 nm; 
nuclear-staining Hoechst channel: λex = 405 nm, λem = 440-470 nm).  
For temperature-dependent experiments, all buffers and media were 
kept at the respective temperature (i.e. 4 oC, 25 oC or 37 oC) for 1 h prior to use. 
HeLa cells were pre-incubated for 1 h at 4 oC, 25 oC or 37 oC, respectively, 
followed by treatment with 50 nM of CPD-BSA for an additional hour. Upon 
washing with PBS (containing 0.1 mg/mL heparin) for three times, then re-
introduction of DMEM, CLSM was immediately performed. For real-time 
imaging of CPD-BSA cellular uptake and sub-cellular localization, HeLa cells 
were first stained with Hoechst and LysoTracker™ DND-99 for 15 min at 37 
oC. Upon washing, the cells were treated with 50 nM of CPD-BSA in DMEM 
medium, and immediately imaged over the course of 30 min (LysoTrackerTM 
channel: λex = 585 nm, λem = 600-650 nm).  
For 3D imaging, HeLa cells were treated with 50 nM of CPD-BSA for 
different periods of incubation time (15, 30, 60, 120, 240 min). Co-staining was 
done with LysoTracker™ and Hoechst 15 min prior to the termination of protein 
delivery. Upon washing (with PBS containing 0.1 mg/mL heparin) and re-
introduction of DMEM medium, cells were imaged with the FV1000-X81 
confocal microscope (Olympus) equipped with a 40× water immersion 
objective and the corresponding filters. Images were processed with the 
VOLOCITY software. Step size: 0.186 µm. Detection channels used were 
mostly similar (CPD-BSA channel: λex = 640 nm, λem = 660-750 nm) 
(LysoTrackerTM channel: λex = 561 nm, λem = 580-650 nm) (Hoechst channel: 
λex = 405 nm, λem = 415-475 nm).  
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5.3.4.2. Flow Cytometry, HCS and In-gel Fluorescence Scanning 
For Flow Cytometry (FACS) experiments, HeLa cells were seeded in a 
12-well plate (Greniner CELLSTAR®) and cultured overnight. Upon medium 
removal, the cells were washed three times with PBS and treated with 50 nM of 
CPD-Protein in DMEM medium. The cells were incubated for 1 h at 37 oC and 
washed three times with PBS (containing 0.1 mg/mL heparin). For protein 
transfection experiments, an equal amount of proteinCy5 was transfected with 
the Pro-JectTM Protein Transfection reagent as earlier described. Co-staining 
with Hoechst was done, where necessary, and the resulting cells were first 
imaged with In-Cell Analyzer 2200 (for HCS image acquisition), where 
applicable, before being detached from the plate by treatment with 200 μL of 
0.1% trypsin-EDTA at 37 oC for 2 min. The detached cells were collected by 
centrifugation (at 700 × g for 2 min) at 4 oC. Upon further washing with cold 
PBS (200 μL) three times, the cells were suspended in 500 μL of PBS. 
Experiments with HeLa cells treated with only proteinCy5 (CPD- and 
transfection-free) were concurrently carried out as negative controls. Cells were 
analyzed and counted/quantified on laser excitation at 640 nm on a BD 
AccuriTM C6 cell analyzer (min. 10000 cells were counted; ex = 640 nm). For 
analysis of protein content, where applicable, the corresponding SDS-PAGE 
separation followed by in-gel fluorescence scanning was concurrently done on 
lysates collected from the same batches of cells.  
For temperature-dependent experiments, all buffers and media were 
kept at the respective temperature (i.e. 4 oC, 25 oC or 37 oC) for 1 h prior to use. 
HeLa cells were pre-incubated for 1 h at 4 oC, 25 oC or 37 oC, respectively, 
followed by treatment with 50 nM of CPD-Proteinfor an extra hour. Upon 
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washing with PBS (containing 0.1 mg/mL heparin) for three times, cells were 
treated in the same way as described above. For time-dependent experiment, 
cells were treated with CPD-Protein (50 nM) for 15, 30, 60, 120, 240, and 480 
min, respectively, before washing. HeLa cells treated with 50 nM of proteinCy5 
(CPD- and transfection-free) alone for 480 min were done concurrently as 
negative controls. Then, the cells were analyzed in the same way as described 
above. For concentration-dependent experiments, cells were treated with CPD-
Protein (5, 10, 50 and 100 nM) for 480 min before washing. Cells treated with 
100 nM of proteinCy5 (CPD- and transfection-free) were done concurrently as 
negative controls. Then, the cells were analyzed in the same way as describe 
above. 
For CPD experiments in different cell lines (PC3, MCF-7, NIH 3T3, 
A549, HeLa), the corresponding cells were incubated with 50 nM CPD-BSA 
(red; CPD-BSA, λex = 632 ± 22 nm, λem = 684 ± 25 nm) for 1 h before washed 
and imaged by In-Cell Analyzer 2200. 
For imaging-based, high-content screening (HCS) experiments with live 
cells, HeLa cells were seeded at 12-well plate and grown until 60~70 % 
confluency and then were treated at desired concentrations and time. After 
incubation, HeLa cells were washed with PBS (containing 0.1 mg/ml Heparin) 
three times. DMEM were then introduced before images were acquired. The In-
Cell Analyzer automated fluorescence imaging system (GE Healthcare) was 
used for automated image acquisition. Images were acquired with a 20× 
objective. The instrument acquired three images of each well randomly with a 
laser-based autofocus system Hoechst (λex = 390 ± 18 nm, λem = 432.5 ± 48 nm), 
CPD-Protein (λex = 632 ± 22 nm, λem = 684 ± 25 nm) and Bright-field (λex = 
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542 ± 27 nm). All images were taken at the same exposure time for the same 
batch of experiments ranging from 1500 to 3000 ms, depending on the intensity 
of fluorescence. The signals would be neither too weak to detect nor 
overexposed. On average, around 300 cells were analyzed in each well. To 
quantify the fluorescence signals, images were processed with In-Cell 
Developer Toolbox software 1.9.2 to identify individual cells and CPD-Protein 
within these cells by following vendor’s protocols. Both the nucleus and CPD-
Protein were segmented via intensity method to remove background first. Then 
they were filtered via sieve operator to refine a segmented image (nucleus: 
greater than 20 µm2; CPD-Protein: greater than 50 µm2) to remove objects or 
artifacts belonging to a particular size range. Finally, the nucleus were measured 
by the counts and CPD-Protein was measured by the sum of fluorescent 
intensity.10  
Sum of 𝐂𝐏𝐃 − 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 Intensity
Count of Hoechst
 
The above formula was used to calculate the average intensity of 
delivered CPD-Protein in each cell. The intensity of three images was used to 
calculate standard errors and the average intensity of those images was regarded 
as the fluorescence readout for a particular sample.  
5.3.4.3. Cytotoxicity Assay  
Cell viability was determined using XTT colorimetric cell proliferation 
kit (Roche) following manufacturer’s guidelines.7,169,194 HeLa were seeded in a 
96-well plate and grown to 50~60% confluency. Cells were treated in duplicate 
with CPD-Protein complex (50 nM) in 0.1 mL DMEM medium.  Equal 
amounts of proteinCy5 were transfected with Pro-JectTM reagent in serum-free 
medium. Control experiment were done concurrently with PBS buffer alone. 
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The cells were incubated for 1 h at 37 oC before washing with PBS (containing 
0.1 mg/mL heparin) for three time. Subsequently, the DMEM medium was re-
introduced into the cells followed by further incubation for 12 h. Then 
proliferation was assayed by using the XTT colorimetric cell proliferation kit 
(Roche) following the vendor’s protocol (read at 450 nm, ref. at 650 nm). Data 
represented the average (s.d. for two trials).  
5.3.4.4. Mechanistic Studies of CPD-Assisted Protein Uptakes.  
HeLa cells were seeded in a 12-well dish and grown until 50~60% 
confluency. Upon removal of the media, the cells were incubated for 30 min at 
37 oC with one of the specific inhibitors at the specified concentration (4.8 mM 
for 5, 5’-dithioobis-2-nitrobenzoic acid, 10 μg/mL for chlorpromazine, 50 nM 
for wortmannin and 50 μM for methyl-β-cyclodextrin) in DMEM medium. 
Then, cells were treated with 50 nM of CPD-Protein complex, during which 
period the inhibitor concentrations were kept constant.195-197 Upon 1 h 
incubation at 37 oC, the cell medium was removed by aspiration. Upon washing 
with PBS (containing 0.1 mg/mL heparin) for three times, the cells were imaged 
by HCS with In-Cell Analyzer 2200, analyzed by FACS as earlier described. 
5.3.5. CPD-Assisted Delivery of Functional Caspase-3  
For CPD-Casp-3 preparations, 5 μM of recombinantly purified, 
functionally active (His)6-tagged caspase-3 (stock: 20 µM in buffer containing 
50 mM HEPES, 10% glycerol, 100 mM NaCl, 5 mM β-ME, pH = 7.0)1 were 
incubated with 15 μM Ni-NTACPD for 15 min on ice in a HEPES buffer (10 mM 
HEPES, pH = 7.9) to form CPD-Casp-3 complex. As a cysteine protease, the 
availability of the active-site cysteine residue is essential to the caspase activity. 
Due to the presence of trace amount of the iodoacetamide terminator (T) in Ni-
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NTACPD which could not be removed completely after the polymer was 
synthesized and purified, the enzymatic activity of CPD-Casp-3 was partially 
inactivated prior to being delivered to cells, as a result of alkylation of the 
active-site cysteine by iodoacetamide. Furthermore, the presence of DTT in the 
enzymatic assay might help to restore some of the caspase enzymatic activity, 
by successful reduction of any oxidized active-site cysteine. Therefore, caspase-
3 enzymatic assays were performed by following published protocols, with and 
without DTT.198 Briefly, 50 pM of CPD-Casp-3 was incubated with 1 μM of 
Ac-DEVD-AMC (#BML-P411, Enzo Life Sciences) in HEPES buffer (50 mM 
HEPES, 50 mM NaCl, 0.1% CHAPS, 10 mM EDTA, 5% glycerol, 10 mM DTT, 
pH = 7.2), as well as in DTT-free HEPES buffer, at 25 oC, respectively. 
Liberation of fluorescence (λex = 360 ± 40 nm and λem = 460 ± 40 nm) was 
recorded by using a BioTek Synergy 4 plate reader until the fluorescence signals 
were saturated. All measurements were performed in duplicate. Control 
experiments were done with recombinant (His)6-tagged caspase-3 (the one prior 
to complexation with Ni-NTACPD) of equal amounts and incubated with the same 
substrate under the same conditions in HEPES buffer). HEPES buffer (with 
DTT) incubated with substrate under the same condition were carried out as 
negative controls. For protein transduction experiments, different 
concentrations of CPD-Casp-3 (final Conc.: 25, 50, 100 nM) were incubated 
with HeLa cells in a 96-well plate. Control experiments were done concurrently 
with HeLa cells treated with Casp-3 (CPD-free) or Ni-NTACPD alone, 
respectively. After 8 h incubation, XTT assay was carried out to test the extent 
of cell death/apoptosis caused by the successfully intracellularly delivered 
active caspase-3. For imaging-based determination of intracellular caspase-3 
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activity, HeLa cells grown in a 4-well imaging petri dish were similarly treated, 
by incubation with CPD-Casp-3 of different concentrations (50 nM) for 2 h. 
Control experiments were done concurrently with cells treated with buffer, 
caspase-3 (50 nM) or Ni-NTACPD alone, respectively. At the end of the 
experiments, cells were washed with PBS (containing 0.1 mg/mL heparin) for 
three times, then incubated with 40 μM Ac-DEVD-AMC for 2 h at 37 oC before 
being imaged on a fluorescence microscope (λex = 405 nm, λem = 420-500 
nm).13a In experiments where mammalian lysates were used to determine 
caspase-3 activity and the amount of cleaved PARP1 formation, the lysates from 
above treated cells were prepared, and used for 1) caspase-3 enzymatic assay 
(25 μg of lysate, 1 μM Ac-DEVD-AMC, same conditions as above), and 2) 
SDS-PAGE followed by Western blotting (WB) analysis of cleaved PARP1 and 
(His)6-tagged caspase-3 as previously described.
30,150 
5.3.6. CPD-Assisted Antibody Delivery 
For CPD-Ab preparation, 5 µM of TCO-AbFC was mixed with 20 µM 
of TzCPD. The product was formed within minutes and used directly (Figure 
S2). HeLa cells were treated with 50 nM of CPD-Ab for 1 h. Upon washing 
with PBS (containing 0.1 mg/mL heparin) for three times, cells were stained 
with Hoechst (15 min) and imaged (CPD-Ab channel: λex = 488 nm, λem = 500-
560 nm; Hoechst channel: λex = 405 nm, λem = 440-470 nm).  
5.3.7. CPD-Assisted Delivery of Small Molecule-Loaded MSNs 
MSNs were synthesized according to previously reported methods with 
some modification.150,176 Most other experiments were performed based on 
published protocols with some necessary modifications.150 Briefly, CTAB (0.1 
g, 0.28 mmol), dissolved in a mixture of H2O (48 mL) and NaOH (2 M, 0.35 
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mL), was stirred and heated to 80 oC under a nitrogen atmosphere. TEOS (0.5 
mL, 2.24 mmol) was then added to the solution and stirred continually. After 
15 min reaction, TPMP (0.13 mL, 0.68 mmol) was slowly added to the mixture. 
After the solution was stirred at 80 °C for 2 h, the formed nanoparticles were 
ﬁltered, washed with MeOH and H2O before dried in the freeze dryer overnight. 
In order to remove the surfactant from the nanopores of the nanoparticles, the 
as-synthesized nanoparticles (0.1 g) were suspended in MeOH (10 mL) and HCl 
(0.6 mL, 37.4%), and the solution was heated under reﬂux for 24 h. the 
nanoparticles were obtained via centrifugation and washed with ethanol for 
three times and water for three times. The product was dried in freeze dryer 
overnight to generate MSN-PO4
-. For the FITC-labeled mesoporous silica 
nanoparticles, first, (3-Aminopropyl) triethoxysilane (APTES, 25 µL) was 
reacted with fluorescein isothiocyanate (FITC, 2 mg) in 0.5 mL ethanol 
overnight. CTAB (0.1 g) was first dissolved in distilled H2O (48 mL) and NaOH 
(2 M, 0.35 mL), followed by heating the solution to 80 °С. TEOS (0.5 mL) was 
added to the solution. 15 min later, the above APTES-FITC solution (30 µL) 
and TPMP (0.13 mL, 0.68 mmol) were added while stirring was continued. 
After the stirring for 2 h, the nanoparticles were obtained by the filter. Finally, 
MSNs with CTAB template were refluxed for 6 h in a nitrogen atmosphere 
followed by extensive washes with methanol and deionized water and CTAB 




- (1.0 mg/mL) was incubated in 1 mM of Dox stock 
solution in PBS buffer (10 mM, pH = 7.4) for 24 h, respectively. After that, the 
solutions were centrifuged (10000 rpm, 10 min) and washed with water twice 
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to remove the Dox molecules absorbed physically on the outer surface of the 
silica. The loading efficiency were determined by measuring the UV-vis 
spectrum of the supernatant and the stock solutions. Then the Dox-loaded MSNs 
(MSN-Dox) were redisposed in the PBS buffer before capped with BiotinCPD of 
different concentrations (10, 20, 50, 100, 150 µM). The mixtures were stirred 
for 2 h at 37 oC. After that, the resulting CPD-MSN-Dox were obtained by 
centrifugation and washed twice with PBS buffer. The nanoparticles were dried 
in the freeze dryer overnight. The nanoparticles were characterized via SEM, 
TEM, FTIR, DLS and Zeta potential. For following experiment, we use CPD-
MSN-Dox that was capped with 50 µM BiotinCPD. 
In a typical experiment, CPD-MSN-Dox was dispersed in PBS buffer 
at 37 oC (final Conc.: 0.1 mg/mL). Aliquots were taken from the suspension in 
a certain time and the delivery of Dox from the pore to the buffer solution was 
monitored via the UV absorbance at 480 nm. 
HeLa cells were treated with 20 µg/mL of CPD-MSN-Dox (1.0 mg/mL 
in PBS) in DMEM for 3 h, 6h, 12 h or 24 h. Cells treated with MSN-Dox for 12 
h and 24 h were carried out concurrently as controls. After incubation, HeLa 
cells were washed with PBS (containing 0.1 mg/mL heparin) three time before 
being imaged (Dox channel: λex = 488 nm, λem = 580-650 nm; MSN channel: 
λex = 488 nm, λem = 500-560 nm; Hoechst Channel: λex = 405 nm, λem = 440-
470 nm). The same experiment was carried out in 6-well plate. After 24 h 
incubation time, the pallets were collected for subsequent enzymatic assays (25 
µg lysate, 1 µM Ac-DEVD-AMC) as described above. WB analysis of caspase-
3 and cleaved PARP1 was also carried out for the same batch of HeLa lysates. 
XTT assay was carried out on HeLa cells treated with CPD-MSN-Dox (24 h 
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treatment) to evaluate the percentage of cell apoptosis caused by the 
intracellular release of Dox, as previously described.150 
5.3.8 NMR
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5.3.9 High-resolution Mass Spectrometry
  
  





The aim of the thesis include the development of novel HTP platforms 
for drug discovery and new strategies for highly efficient intracellular drug 
delivery.  
Advances in genomic science and combinatorial chemistry provide the 
opportunities and possibilities for rapid drug development. Therefore, it is 
urgent to develop the high throughput screening strategies for the lead discovery 
and following up validation.  
In chapter 2, we have successfully fabricated a 396-member peptide-
hybrid small molecule microarray as a high-throughput platform for convenient 
profiling of SH2 domains. By screening the library against 15 SH2 domains, an 
informative fingerprint was generated which clustered the various SH2 domains 
according to their functional class. Further, ligands PP-pY-X5, PP-pY-X25, PP-
pY-X1 were identified as putative small molecule hits against Lck and Grb2. In 
future, these peptide-hybrid compounds might be converted into small 
molecule-based cell-permeable protein-protein inhibitors. Further, a dual colour 
strategy might be applied to monitor the slight differences in SH2 domains. 
In chapter 3, the first microarray-based platform, enabling rapidly 
identifying on- and off-target of drug like compound from live cells was 
established. Compared to gel-based scans and PDs/WBs, our microarray 
provided the possibility of high-throughput validation with less sample 
consumption but comparable sensitivity. In this experiment, we have 
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successfully profiled a panel of drug-like ABP and AfBP bioactive compounds 
against six antibodies, and have likely identified PKA as the off-target for P1 
and PU-1. It should be noticed that the quality of antibodies used plays critical 
roles in the reliability of the readout. Further large-scale validation such as 
WBs/PDs were required for the potential off-target identified from microarray. 
Overall, microarray-assisted strategies provide possibility for high-
throughput screening approaches, for hit-identification, lead-optimization and 
off-target screening in drug discovery application. 
Once lead compounds are identified, it requires further optimization in 
terms of solubility and cell-permeability. In spite of the effort on optimization, 
approximately 40% of currently available drugs and up to 75% of compounds 
under development have been estimated as poor water-soluble. The issue 
become more pronounced for macromolecules such as proteins and 
DNAs/siRNAs which emerge as another branch of therapeutic drugs. Therefore, 
the development of efficiently drug delivery strategy is urgently needed. 
In chapter 4, we have successfully designed and synthesized several 
novel cell-penetrating poly(disulfide)s. These CPDs, upon conjugate to cargos 
including recombinant proteins and suitably modified antibodies via either 
covalent or non-covalent biorthogonal strategies, are able to rapidly and 
efficiently deliver those cargos into different mammalian cells via endocytosis-
independent pathway. Rapid intracellular CPD depolymerization of the 
delivered cargos under highly reduced cytosolic environments subsequently 
released the protein in their functionally active form, which may be further 
translocated to their intended subcellular organelles for additional biological 
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process. The successful delivery of antibodies indicates this strategy may be 
more broadly applicable in further for effective intracellular delivery of other 
therapeutic antibodies. Besides, we have successfully developed CPD-capped 
MSNs for encapsulation of native small molecule drugs without the need of 
chemical modification. With doxorubicin as an example, we found CPD-MSN-
Dxo entered mammalian cells rapidly and was able to subsequently release free 
Dox into cytosol. 
Compared to existing strategies, the key advantages are their versatility 
and flexibility, enabling immediate delivery of a variety of cargos with 
minimum chemical modification. Further, the rapid and “biorthogonal” cargo-
loading process enables the preparation of CPD-cargo conjugation in a matter 
of minutes under aqueous conditions, accelerating the cell delivery study. The 
minimal cell cytotoxicity further highlights the unique advantage of this new 
cell-transduction method over others. 
Future work will focus on the expansion of the type of CPDs by using 
other conjugation chemistries, application of these CPDs for cell type specific 
delivery of other therapeutically important drugs and further animal-based 
therapeutic drug delivery. 
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